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Opgedragen aan mama
(1943 – 2001) 
Grow old along with me!
The best is yet to be,
The last of life, for which the first was made.
Robert Browning
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INTRODUCTION AND MAIN RESEARCH QUESTIONS
1. INTRODUCTION
1.1 An ageing population
Population ageing is a global demographic trend and is expected to continue in fu-
ture decades due to increasing life expectancy and consistently low levels of ferti-
lity over the past decades. Together with a growing number of ageing baby boomers, 
this trend will result in a changed population pyramid with a narrowing base and a 
larger top (1) (Fig. 1).
In addition there is the progressive ageing of the older population itself. The pro-
portion of “oldest-old” (those aged 80 and over) is growing faster than any other 
segment of the population and is projected to almost treble by 2060 (Fig. 2) (1). 
Remarkable improvements in life expectancy over the past century also meant a 
shift in the leading causes of disease and death, with an emerging importance of 
chronic and degenerative diseases like cancer, heart disease, and diabetes (2). 
Figure 1. Future-oriented version of the population pyramid (2010 and 2060) 
Demography report 2010. European Commission; 2011.
2010 (bordered): observed populations
2060 (solid colour): EUROPOP 2008 convergence scenario
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1.2 Ageing and cancer 
Over a third of all cancers are diagnosed in individuals over the age of 75 (3). The 
association between ageing and cancer may be explained by two mechanisms: i) 
carcinogenesis occurs over time and ii) the molecular changes of ageing enhance 
the susceptibility of ageing cells to carcinogenesis (4). Following on global aging, one 
can expect the incidence of cancer to further increase in the coming decades (2). 
A quarter of cancers in males aged 75 and over are prostate cancers while lung and 
bowel cancers contribute 17% and 15% respectively of cases in this age group. Bre-
ast (21%), bowel (15%), and lung (15%) cancers are the most common neoplasms in 
females aged 75 and over (3). Unlike the mortality of cardiovascular diseases, which 
is declining among persons of all ages, the mortality of cancer is rising for individu-
als above the age of 65 (4). In 2010, in Europe, cancer was the second most common 
cause of death at old age with over half of cancer deaths occurring in people aged 
65 years and over (3;5). Therefore, in the last decade, geriatric oncology has beco-
me an evolving field of interest. Research, however, has mainly concentrated on 
solid tumours, while in older adults, haematological malignancies constitute a com-
mon cause of morbidity and mortality as well. 
Figure 3 shows age-specific incidence rates (per 100.000) for lymphoid and myeloid 
malignancies, by age class (6). Incidence for both increases steadily with advancing 
age, reaching a maximum between 75 and 99 years. Approximately one fifth of hae-
matological malignancies in older individuals constitute aggressive disease, like acu-
te myeloid leukemia (AML), or high-grade lymphoma, that will shorten the patient’s 
Figure 2. Demographic trends in Belgium and Europe 
Demography report 2010. European Commission; 2011.
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life and may cause severe discomfort (7). As yet, available evidence in older patients 
with haematological malignancies is derived primarily from studies in which, besides 
patients with solid tumours, a limited number of haematological patients were in-
cluded. Research, purely focusing on older patients with haematological malignancies, 
is therefore much-needed. 
In view of the research project this introduction will further focus on 
• haematological malignancies with higher incidence and unfavourable 
prognosis in older individuals,
• the heterogeneity of ageing, 
• comprehensive geriatric assessment and screening, and
• treatment principles in older patients with haematological malignancies
INTRODUCTION AND MAIN RESEARCH QUESTIONS
Figure 3. Age specific incidence rates for haematological malignancies (2000-2002)  
Sant et al. Blood 2010; 116(19): 3724-34.
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1.3 Haematological malignancies in older patients
Taking incidence rates and prognosis into account, and in close collaboration with 
the haematologists in our hospital, this research project will focus on 4 subtypes 
of haematological malignancies, i.e. acute myeloid leukemia, non Hodgkin lympho-
ma (NHL), myelodysplastic syndromes (MDS) and multiple myeloma (MM).
1.3.1 Acute myeloid leukemia 
Acute myeloid leukemia is characterized by the malignant transformation of mye-
loid stem cells in the bone marrow, which are incapable of normal differentiation 
and maturation, resulting in “blast” cells. AML incidence is strongly related to age: 
age-specific incidence rates rise gradually from around the age of 40 with the hig-
hest rates in the 85+ age group (fig. 3). Compared with younger patients, AML in 
older patients emerges more often secondary to myelodysplasia or chemotherapy 
for a previous cancer or an auto-immune disease, and is more frequently associated 
with an unfavorable karyotype and expression of MDR1 (encoding for multidrug 
resistance) (8).
1.3.2 Non Hodgkin lymphoma
Non Hodgkin lymphoma is the most common malignant disease of the lymphatic 
system and is most frequently diagnosed among older people aged 65 to 74 with 
a median age of 66 years, while 9.4% of patients are 85 years or older (9). Non Hod-
gkin lymphoma is not a single disease, but rather a group of several closely related 
entities. The World Health Organization estimates that there are at least 61 types 
of NHL. Non Hodgkin lymphomas are broadly divided into two major groups: B-cell 
lymphomas, accounting for 85 percent of all NHLs, and T-cell lymphomas. NHLs 
may also be classified as indolent or aggressive. Diffuse large B-cell lymphoma 
(DLBCL) is accounting for more than 80% of aggressive lymphoma’s and is the most 
frequent subtype of NHL in older people, with poorer prognosis than in younger 
patients. Other subtypes commonly associated with a poor prognosis, like the 
morphologically defined immunoblastic variant, the activated B-cell (ABC) subtype 
and the Epstein-Barr virus (EBV)–positive DLBLC, are all overrepresented in older 
patients (10-12). 
1.3.3 Myelodysplastic syndrome(s)
Myelodysplastic syndrome is a disease of older people, with a median age at diag-
nosis of 70 years. The incidence of MDS in Europe is about 4 cases/100 000 inha-
bitants/year, reaching 40–50/100 000 in patients aged ≥70 years (13). MDS is charac-
terized clinically and morphologically by ineffective hemopoiesis leading to bone 
marrow failure. Haematopoietic progenitors show a decreased capacity for diffe-
rentiation and an increased tendency for apoptosis (14). Patients with MDS suffer 
from chronic cytopenias that may lead to recurrent transfusions, infections, and 
increased risk for bleeding. Incidence of secondary MDS, occurring after cytostatic 
treatment for cancer or prolonged immunosuppressive therapy, is increasing and 
is associated with a poor prognosis. Moreover, patients with MDS are at risk for 
progression to AML. 
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1.3.4 Multiple myeloma
Multiple myeloma is most frequently diagnosed among older people aged 65 to 74 
with a median age of 69 years, while 9.3% of patients are 85 years or older (9). MM 
is characterized by a proliferation of malignant plasma cells producing monoclonal 
immunoglobulin (M protein) and invading and destroying adjacent bone tissue. The 
presentation of MM can range from asymptomatic to severely symptomatic. Ma-
nifestations include bone pain, bleeding, recurrent infections, renal failure, and 
pathologic fractures with spinal cord compression. The International Myeloma 
Working Group agreed on diagnostic criteria for symptomatic myeloma as well as 
asymptomatic or smouldering myeloma as shown in table 1 (15).
Table 1. Diagnostic criteria for multiple myeloma and smouldering multiple myeloma  
Raykumar et al. Lancet Oncol 2014; 15(12): e538-48.
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1.4 The heterogeneity of ageing
As people get older there is an increasing heterogeneity in health as well as in physi-
cal, mental and cognitive functioning.
1.4.1 Defining an older patient
To define “an older patient”, the concept of chronological age might seem easy and 
practical. There is, however, no generally accepted age cut-off defining an older 
patient, leading to substantial differences in lower age limits throughout studies. 
In most haematological cancer trials, the lower age limit to define older patients is 
arbitrarily chosen between 60 and 70 years of age (16-25). In a retrospective analysis 
of a population-based non Hodgkin lymphoma registry patients were considered 
old once complete remission (CR) and overall survival (OS) rates decreased (26). De-
finition of older age therefore differed according to histological type. Patients with 
indolent lymphomas were considered old as from the age of 70, while for patients 
with aggressive lymphoma older age was defined as 65 and over. Eventually, in 
some cancer studies, lower age thresholds are determined by treatment intensity. 
In a study on “older” transplant recipients, an age limit of 50 years has been adop-
ted (27). Although a generally accepted age cut-off could resolve this variety in age 
limits, chronological age does still not take into account another important aspect 
of ageing, i.e. the heterogeneity of ageing.
1.4.2 Chronological age versus biological age 
Ageing is a highly individualized and very heterogeneous process with a broad spec-
trum ranging from older persons who are functionally independent to those who are 
at high risk of functional decline and mortality and all the others in between. Chro-
nological age does not reflect this variability, both between and within individuals 
(28). Biological age on the other hand is believed to reflect a person’s remaining func-
tional reserves and life expectancy. Figure 5 is a clear example of the difference be-
tween chronological and biological age. Instead of an average life expectancy, it re-
presents the distribution of life expectancy, according to age and sex, thereby 
illustrating the substantial variability in life expectancy that exists at each age. Bio-
logical age, therefore, might help clinicians to predict whether a specific patient is 
expected to live longer or shorter than an average patient of the same age. For in-
stance, patients with severe comorbidities like end-stage renal disease or stage IV 
chronic obstructive lung disease, and functionally dependent, bedridden patients, 
will have a life expectancy that is substantially lower than average for his/her age 
category. High-functioning older adults without comorbidities worth mentioning, on 
the other hand, might likely live substantially longer than their contemporaries. Un-
fortunately, for most patients, there is no simple way to assess biological age. The 
best tool available to date is a comprehensive geriatric assessment (CGA). As explain-
ed below, a CGA exploring all domains likely to undergo age-related changes, allows 
a more accurate estimation of the patient’s active life expectancy and functional 
reserve than a standard clinical evaluation. (4;28). 
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As previously mentioned, ageing is a highly individualized and very heterogeneous 
process. As people get older, there is an accumulation of impairments in multiple 
physiological systems resulting in a decrease in physiological reserves and functi-
onal status and an increase in their vulnerability to adverse outcomes (29). The vul-
nerable subset of this ageing population has also been identified as “older adults 
with comorbidity” or “those who are disabled”. Although distinct clinical entities, 
the terms of comorbidity, disability and frailty are often used interchangeably (30). 
The distinction between these entities is one of the cornerstones of this thesis. 
1.4.3 Comorbidity, disability and frailty
Comorbidity can be defined in several different ways. In the light of this thesis co-
morbidity refers to the simultaneous presence of multiple health conditions with 
an index condition, in this case, cancer and other unrelated conditions. The presen-
ce of comorbidity increases with age (31). Therefore, in an ageing population, one can 
expect a growing percentage of patients with a diagnosis of cancer and other me-
dically relevant conditions in addition. The presence of comorbidity might adver-
sely affect outcome. Comorbidity has been associated with mortality, hospitaliza-
tion and longer hospital stays, institutionalization, lower quality of life, loss of 
INTRODUCTION AND MAIN RESEARCH QUESTIONS
Figure 5. From Walter et al. JAMA 2001; 285 (21): 2750-2756
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physical functioning, depression, multiple drug use and higher health care utiliza-
tion and costs (32). Its measure in research studies, especially in older individuals, 
has therefore become increasingly important. In theory, a simple count of chronic 
conditions can be used as a measure for comorbidity. However, the impact of co-
morbidity is related, not only to the number of chronic conditions, but also to their 
degree of severity. Several indices have been described to measure comorbidity. 
The Cumulative Illness Rating Scale-Geriatrics (CIRS-G) is one of the most frequent-
ly used, valid comorbidity instruments (appendix 1) (33). The CIRS-G score correlates 
with mortality, hospitalization rate and duration, hospital re-admission, medicati-
on usage, abnormal laboratory test results, and functional disability in geriatric 
populations. In older cancer patients, CIRS-G also correlates with progression-free 
survival (34). It takes into account total number as well as severity of comorbid con-
ditions. Therefore, during this research project, comorbidity has been measured 
using CIRS-G. However, the impact of comorbidity is related, not only to the number 
of chronic conditions, but also to their degree of severity. Several indices have been 
described to measure comorbidity. The Charlson comorbidity index (CCI) and the 
CIRS-G are two of the most frequently used, valid comorbidity instruments. The 
CCI correlates with mortality risk, postoperative complications, length of hospital 
stay and discharge to a nursing home. In older cancer patients, CCI correlates with 
progression free survival (PFS). Its performance in predicting mortality and length 
of stay compares very well with the CIRS-G. The CIRS-G (appendix 1) score corre-
lates with mortality, hospitalization rate and duration, hospital re-admission, me-
dication usage, abnormal laboratory test results, and functional disability in geri-
atric populations. In older cancer patients, CIRS-G also correlates with PFS (34). In 
the CIRS-G every disease requires grading, thus taking into account not only the 
number but the severity of comorbid conditions as well and making it the most 
detailed. In addition, the rating manual is aimed at a geriatric population and the-
refore includes details on several geriatric problems (35). Therefore, during this re-
search project, comorbidity has been measured using CIRS-G. 
Disability, according to the International Classification of Functioning, Disability 
and Health (ICF), is defined as “an impairment, activity limitation or participation 
restriction that is the result of the interaction between contextual factors (perso-
nal and environmental) and health conditions”(36). Disability is mainly the resultant 
of diseases and physiologic alterations with ageing on one hand and social, eco-
nomic, and behavioral factors as well as access to medical care on the other. In the 
narrow sense, disability is “the difficulty of coping with self-care tasks (Activities 
of Daily Living, ADL) and tasks of household management (Instrumental Activities 
of Daily Living, IADL)” (32). The likelihood of developing a disability rises steadily 
with age. In the Participation and Activity Limitation Survey in Canada in 2006, 
the disability rate tripled from 23 percent among individuals age 55 to 64 to 73 
percent among individuals age 85 and older (Fig. 4) (37). Mobility and agility disabi-
lities were the most common disabilities experienced by older people as shown in 
table 2 (37). Most people with disabilities have more than one type of disability. 
Disability has been associated with mortality, hospitalization, length of hospital 
stay and institutionalization (32).
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Frailty is characterized by an age-related increased vulnerability to stressors due 
to decreased physiological reserves and/or dysregulation in multiple physiologic 
systems. This results in difficulties to maintain homeostasis in response to “normal” 
perturbations that would not create such problems at younger age (38). The definiti-
ons of ageing and frailty share a basis of failure in homeodynamics, but with ageing 
this failure is global whereas in frailty loss of homeostasis is related to energy me-
tabolism and neuromuscular changes. Frailty is a risk factor for adverse health out-
comes, not just in terms of morbidity and mortality, but also with regard to disabi-
lity, dependency, falls and institutionalization. Although the concept of frailty has 
gained considerable attention during the last decades, consensus is still lacking on 
its definition and the criteria that should be used for its recognition. Therefore es-
timates of prevalence differ widely. The most frequently used operational definiti-
on is the “phenotype of frailty” proposed by Fried et al. Frailty was assessed based 
on the identification of five criteria: (1) low handgrip strength; (2) self-reported fati-
gue; (3) unintentional weight loss; (4) reduction of physical activity; and (5) slow 
walking speed. Older persons are considered pre-frail or frail if they meet at least 
two, respectively three out of these five criteria (30). Based on these Fried criteria, 
in the English Longitudinal Study of Ageing, prevalence of frailty rose with increasing 
age, from 6.5% in those aged 60–69 years to 65% in those aged 90 or over (39). Pivo-
INTRODUCTION AND MAIN RESEARCH QUESTIONS
Figure 4. Disability rates, by age group (%) 
Federal Disability Report: Seniors with Disabilities in Canada. Government of Canada 2015.
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tal to the clinical definition of frailty is the concept that no single altered system 
defines this state, but that multiple systems must be involved. Comorbid diseases 
may contribute to the development of frailty and disability might exacerbate frailty, 
but individual diseases are not sufficient for the identification of frail individuals, 
nor are any two diseases, or disability alone. In the presence of disease, other ma-
nifestations must also be present (30). Frail patients also appear to have specific care 
needs, beyond care of underlying comorbidity and associated disability.
The loss of homeostatic reserve and the development of frailty can be manifested 
in the myriad of geriatric syndromes including falls, delirium, malnutrition, urinary 
incontinence, and deconditioning. However, frailty is a dynamic concept. The pro-
cess of frailty can be changed or reversed with a possibility of transition from being 
frail to less frail or even non-frail if frailty is detected and treated at onset (40). The-
refore, one of the main challenges in geriatrics is the detection of frail individuals 
to determine, by a systematic evaluation or CGA, who might benefit by medical and 
rehabilitation efforts. 
In accordance with the differences in life expectancy in figure 5, a CGA is assumed 
to distinguish between three groups of patients (41, 42). In the literature distinct terms 
are used interchangeably to identify these three patient groups. Most articles fol-
low the criteria as defined by Balducci, identifying fit (group 1), unfit (group 2) and 
frail (group 3) patients (42). A frail patient is then considered a candidate only for 
palliative treatment, while the patients in between might benefit from some spe-
cial (pharmacological) approach. Saarelainen identified robust, prefrail and frail 
individuals while Deschler divided his patients into a low, intermediate and high risk 
group (43, 44). Each one of these classifications fails to recognize the concept of frail-
Table 2. Frequency of type of disability by age group (%)
Federal Disability Report: Seniors with Disabilities in Canada. Government of Canada 2015.
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ty and the goals of a geriatric assessment. As previously mentioned, frailty is a 
dynamic concept with the possibility of transition. The goal of a CGA is to detect 
these frail patients, patients amenable for improvement due to geriatric interven-
tions and follow-up, and thus the patients in between. In the light of this argumen-
tation we’ve defined respectively fit, frail and unfit patients as follows: 
• fit patients are functionally independent patients without medically relevant 
comorbidity 
• unfit patients are identified by the presence of at least one of the following: 
multiple comorbidities, the presence of one or more geriatric syndromes, or 
dependence in ADL. Most patients aged ≥ 85 years are attributed to this group. 
• frail patients represent the group in between with minor dependencies in IADL 
and/or one or two comorbidities in the absence of a geriatric syndrome or 
dependence in ADL.
1.5 Comprehensive geriatric assessment
A CGA is a multidisciplinary, in-depth evaluation to determine an older person’s 
medical, psychological and functional abilities in order to develop a coordinated 
treatment plan with the aim to preserve or restore normal function and indepen-
dence whenever possible (45, 46). Given the reversibility of frailty, as stated above, a 
CGA is especially beneficial to frail individuals. Although no golden standard exists, 
there is a consensus that CGA should include functional, cognitive, emotional and 
psychosocial status as well as the aspects of nutrition, mobility, and polypharmacy, 
in addition to comorbidity assessment (42). Extensive evidence is available for the 
efficacy of a CGA, in a wide variety of settings and patient populations, with bene-
fits related to functional status, mortality, cognition, length of hospital stay and 
rates of readmission and institutionalisation (47-51). 
In the field of geriatric oncology, increasing evidence suggests that a geriatric as-
sessment identifies previously unknown geriatric problems - thereby allowing tar-
geted and tailored interventions-, adds prognostic information, might influence 
treatment decisions and might predict treatment toxicity and/or complications 
(52-60). Quality of life (QoL) parameters, especially patient’s self-reported physical 
symptoms and/or physical functioning, have repeatedly proven to correlate with 
survival (61-63).
There is evidence that, also in patients with haematological malignancies, a geriatric 
assessment can reveal additional health problems, even in apparently fit patients 
(64). Most often, these impairments were not noticed by the treating physician, alt-
hough they might affect prognosis and treatment response. Several studies have 
shown that physical functioning (measured by means of ADL, IADL or objective 
measures like grip strength and short physical performance battery) is an indepen-
dent prognostic predictor for survival (27;61;65-69). In AML patients, both cognitive de-
cline and QoL appeared statistically significant prognostic factors for survival (61;63;65) 
while in older allogeneic haematopoietic cell transplantation recipients low mental 
INTRODUCTION AND MAIN RESEARCH QUESTIONS
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health was associated with inferior OS (27). There is one small study in MDS/AML 
patients that looked at the effects of different treatments on QoL, a much more 
valid outcome parameter for older patients than just survival. At follow-up, up to 
32% of patients showed new functional dependencies while cognitive changes be-
came obvious in a quarter of all patients. Global QoL deteriorated in 1/3 of patients 
(70). Evidence on other CGA domains in this patient group is almost non-existing (71). 
Despite its assumed/proven benefits, an assessment is both time- and staff-con-
suming and might not be necessary for every older patient. Therefore cancer spe-
cialists are looking for a short screening tool that can distinguish between fit older 
cancer patients and more vulnerable (both unfit and frail) patients that should 
subsequently receive a full CGA (72).
1.6 Screening
The challenge of identifying those patients who will most likely benefit from a CGA 
led to the incorporation of a two-step approach. In a first step, patients are screened 
for the presence of frailty, using a validated screening tool. Patients who screen 
negative are likely to be fit and should not be considered differently from younger 
patients. Patients who screen positive require a more in-depth evaluation, linked 
to appropriate geriatric interventions when indicated (73;74). Thus, screening tools 
should have the potential to separate fit older patients from frail and unfit patients 
(75). They should be short and simple with a high sensitivity and negative predictive 
value (NPV), and, if in any way possible, a high specificity as well. Several frailty 
screening tools (Vulnerable Elders Survey (VES-13), G8, Groningen Frailty Index 
(GFI), Geriatric Risk Profile (GRP), abbreviated CGA (aCGA)) are available in geriatrics 
but only two, the aCGA and the G8, were designed specifically to detect frailty in 
older cancer patients (75). None has thus far been validated in patients with a hae-
matological malignancy. 
Patients with a positive screen should not automatically be excluded from standard 
treatment. These patients should undergo a full CGA to detect potential deficits for 
which targeted interventions can be applied, e.g. dietary advice or parenteral nutri-
tion in case of malnutrition. They might still be eligible for a standard approach 
after these geriatric interventions have solved those biological, clinical and/or so-
cial issues limiting the applicability of oncological guidelines (76). If not eligible, tre-
atment modifications and/or the introduction of new agents are currently under 
study for these patients and will likely constitute the future.
1.7 Treating older people with haematological malignancies
In the first paragraph, general treatment principles for older patients are discussed. 
Afterwards, this principles will be applied, as far as evidence is available, for the 
different subtypes of haematological malignancies discussed in this thesis. 
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1.7.1 General treatment principles 
When cancer is diagnosed in an older patient, treatment decisions will often be 
complex. One of the main challenges of treating older patients with cancer is to 
assess whether the expected benefits of treatment are superior to the risks in a 
population with decreased life expectancy and decreased tolerance to stress (77). 
Age is an important adverse prognostic factor due to comorbid conditions, functi-
onal decline, cognitive deterioration, reduced treatment tolerance, poor nutritional 
status and potential drug-drug and drug-disease interactions (78;79). At all ages, pa-
tients with a haematological malignancy will benefit from a significantly better 
overall survival if treatment results in a durable remission. To obtain this remission, 
in most cases, full-dose aggressive therapy is needed (80). Age itself should not pre-
clude patients from full intensity treatment and intensive therapy with curative 
intent should be given to all patients who can tolerate such therapy (41;42;81). Thus, 
older patients, considered fit through screening or CGA, should receive the same 
treatment as their younger counterparts. This was clearly illustrated in a group of 
patients with DLBCL. All patients underwent a CGA and were subdivided in fit and 
unfit patients. For all patients, treatment was chosen according to clinical judge-
ment of the attending physician, who was blind to the results of the CGA. Patients 
considered fit by CGA could be safely treated with aggressive therapy and achieved 
an outcome similar to that of younger DLBCL patients, while in unfit patients full 
therapy could not improve outcome compared with palliative treatment (82). Thus, 
with a life expectancy below that of the cancer-related life expectancy, in unfit pa-
tients, symptom palliation and quality of life preservation are paramount.
The main problem however is the group of frail patients at increased risk for treat-
ment complications. Both cancer and its treatment are significant stressors with the 
potential to challenge physiological reserves (83). A frail older person, in general, will 
no longer be a candidate for aggressive life-prolonging treatment. However, his life 
expectancy, although limited, is not necessarily short, as already illustrated in figure 
5, and usually above that of the cancer-related life expectancy (7). In addition to symp-
tom management and quality of life preservation – pillars of treatment in unfit pa-
tients –, treatment in frail patients should focus on prolongation of active life expec-
tancy (rather than survival), and prevention of adverse drugs reactions (ADRs) (76). 
However, a limited ability to identify frail patients and the systematic underrepre-
sentation of older patients in clinical trials, makes it difficult to define specific treat-
ment strategies in frail older patients (84;85). The absence of studies guiding physicians 
in their choice of the right treatment dose and/or regimen exposes these patients to 
arbitrarily defined dose reductions and/or adaptations in treatment schedules, with 
possible far-reaching consequences (68). Therefore, current research should focus on 
means to describe more accurately the health status of an older individual and on 
the possibilities of an individualized management, tailored to differences in functio-
nal reserve, life expectancy, social and economic support and possible other factors 
(84). This is especially needed in haematology, where some novel treatments became 
available, with good prospects for these frail older patients (80). 
One important point of attention should be made here. Especially in patients with 
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haematological malignancies, there is always the risk that a reduced performance 
status, depending only on advanced and symptomatic disease, might lead to a faul-
ty diagnosis of frailty, with the consequence of undertreatment. 
1.7.2 Acute myeloid leukemia
Treatment options vary from intensive chemotherapy of the same type offered to 
younger patients over non-intensive chemotherapy to supportive care alone. De-
spite the fact that intensive therapy is associated with hospitalization, a high risk 
of complications and a decrease in functional status, a full dose regimen is the only 
available option to achieve a long-term remission (86). It should therefore be consi-
dered, at the very least, in all fit older patients. In younger patients, intensive tre-
atment and particularly the advances in supportive therapy, have steadily improved 
outcome over the last 30 years with currently a 45 -50% 5 year event free survival 
(EFS). Oppositely, in older patients treated with the same regimen, little improve-
ment was seen over the years. Approximately 40-65% will achieve remission but 
85% will relapse within 2 to 3 years, with a 5-year survival rate of about 15% (87). 
Apart from an unfavorable biology, older age itself is hereby an independent risk 
factor (86). Certain groups of patients who are not candidates for intensive chemo-
therapy can be treated non-intensively with chemotherapeutic drugs such as aza-
citidine, a hypomethylating agent, or low-dose cytarabine. Choice of treatment 
hereby is related to pretreatment disease characteristics rather than individual 
patient characteristics. At present, the question remains whether and how these 
regimens can be applied in both frail and unfit patients. Besides the group of pa-
tients in whom just a supportive treatment can be offered given an absolute lack 
of physiological reserves, there is also a group of patients in whom only a suppor-
tive treatment can be applied, not due to a lack of reserves, but as a result of 
non-existing therapeutic alternatives. The latter group can be given purely suppor-
tive care or they can be offered to participate in a therapeutic trial.
In the light of this unfavorable perspective, the impact on quality of life, of disease 
as well as therapy, becomes equally or even more relevant than survival, as already 
mentioned before. Although few studies have been carried out in older AML pa-
tients, QoL has been shown to be compromised at the time of diagnosis. Fatigue 
hereby is a prevalent condition with a negative impact on QoL (16;63). In intensively 
treated patients, QoL decreased during hospitalization but rebounded after dischar-
ge. For those patients who survived beyond six months from diagnosis significant 
improvements were achieved in QoL, fatigue and physical function over time (25;88). 
Overall, 97% of patients confirmed that QoL for them was more important than 
length of life. Compared to intensive chemotherapy, supportive care and cytore-
duction with hydroxyurea do not provide a significantly better perspective in terms 
of improving quality of life (89). For novel treatments like azacitidine no studies could 
be found regarding their impact on QoL.
1.7.3 Non Hodgkin lymphoma
Treatment is usually tailored according to the individual risk profile based on the 
International Prognostic Index (IPI). The IPI is a clinical tool used to predict outcome 
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for patients with aggressive NHL. Based on the number of negative prognostic 
factors present at the time of diagnosis (age > 60 years, stage III/IV disease, eleva-
ted lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group per-
formance status (ECOG PS) ≥ 2, more than one extranodal site of disease), 4 outco-
me groups were identified with a 5-year OS ranging from 26% to 73% (90). The 
Elderly-International Prognostic Model (E-IPI), using an age cut-off of 70 years in-
stead of 60 years, has been recently proposed to refine the risk profile in older 
patients, but still needs validation (91). 
R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab) 
is currently considered one of the most effective first-line treatments for B-cell NHL 
(85), and is the treatment of choice in young patients as well as in fit older patients, 
with 5-year OS rates of about 60% in the older age group (92). In patients over 80 
years of age, reduced doses of CHOP with a conventional dose of rituximab (R-mi-
ni-CHOP) appear feasible with potential long-term cure expectation (93). In frail pa-
tients studies are ongoing as to the best form of treatment, including regimen mo-
difications (73;94), the use of a pre-phase treatment with vincristine and corticosteroids 
(95), and dose modification based on age (93) or CGA results. Monfardini et al. used the 
results of the CGA to select unfit older patients in order to treat them with a less 
toxic combination of vinorelbine and prednisone (96). Main problem was the lack of 
referral. Therefore, patient accrual was low and no firm conclusions could be made 
on treatment effect. Visani et al. evaluated the use of non-pegylated liposomal 
doxorubicin instead of conventional doxorubicin for the treatment of NHL in unfit 
patients, with promising results but study sample was, once again, small with inclu-
sion of 20 patients over an 11 month period (94). In the study by Spina et al., DLBCL 
patients were classified as fit, frail, or unfit based on ADL, IADL, and the presence 
or absence of comorbidities. Drug regimen was adapted according to comorbidity, 
while doses where reduced, dependent on ADL- and IADL-scores. Fit patients recei-
ved full dose treatment while frail and unfit patients received 75% and 50% respec-
tively, of the usual doses. All 3 groups had similar complete remission (CR) rates. 
There was no statistical significant difference between groups in the occurrence of 
severe or life-threatening (grade 3 and 4) toxicities. Survival rates were better in fit 
patients (97). Oliveiri et al. divided patients into fit, frail and unfit patients, based on 
age, ADL, comorbidities, and the presence or absence of geriatric syndromes. In frail 
patients doxorubicin was replaced by pegylated liposomal doxorubicin, while unfit 
patients received a 50% dose reduction (mini-CHOP), without rituximab. No diffe-
rences were found in the rates of complete remission or grade 3 and 4 toxicities. Not 
unexpectedly, OS and EFS were, again, better in fit patients (98). These studies show 
that the results of a CGA can be used as a parameter to modify doses and regimens 
of chemoimmunotherapy in older patients with DLBCL with encouraging results 
regarding treatment-related mortality, toxicity and outcome. 
In current practice, frail and unfit patients, no longer candidate for intensive the-
rapy and not willing to participate in ongoing trials, can be offered rituximab mo-
notherapy. If a patient responds and his condition improves, bendamustine or vin-
blastine can be added. (12;99).
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1.7.4 Myelodysplastic syndrome
Available treatment options range from potentially curative, intensive treatment 
with standard induction chemotherapy and consolidation including stem cell trans-
plantation, over non-intensive chemotherapy to best supportive care alone. (100). 
To assist in decision making regarding treatment, several prognostic systems have 
been developed and validated in patients with MDS. Among these the International 
Prognostic Scoring System (IPSS) is the simplest and most commonly used. The 
IPSS is based upon the cytogenetic abnormalities, the percentage of blasts in the 
marrow and the number of lineages affected in the cytopenia and then stratified 
into four prognostic groups: low, intermediate-1, intermediate-2 and high risk. New 
insights in prognostic variables have led to the development of the Revised IPSS 
(IPSS-R) (table 3), with 5 instead of 4 major prognostic categories thereby allowing 
a better prognostication for survival and evolution to AML (101). This might enable 
earlier recognition of patients at high risk of progression to aggressive disease and 
might consequently optimize treatment timing. Median overall survival (OS) times, 
according to risk group, are 8.8, 5.3, 3.0, 1.6 and 0.8 years for patients with very 
low risk, low risk, intermediate risk, high risk, and very high risk IPSS-R scores. 
Prognostic variable 0 0,5 1 1,5 2 3 4
Medullary blasts (%) ≤2 - >2-<5 - 5-10 >10 -
Cytogenetics very good - good -
inter-
mediate poor
very 
poor
Hemoglobin ≥10 - 8-<10 <8 - - -
Platelets ≥100 50-<100 <50 - - - -
Absolute neutrophil count ≥0.8 <0.8 - - - - -
To date, the only curative treatment is allogeneic stem cell transplantation. Recent 
studies in reduced-intensity-conditioning HSCT patients have shown that perfor-
mance status as well as comorbidities are major prognostic parameters, whereas 
age is not (102-105). However, only a minority of patients in excellent health are eligible 
for this therapy (41). Therefore, in the group of high-risk patients, azacitidine should 
be considered. With azacitidine, although not curative, OS was significantly incre-
ased when compared to conventional care regimens. Moreover, median time to 
AML transformation was longer and rates of complete and partial remission and 
any haematologic improvement were significantly higher. Subgroup analysis in pa-
tients ≥ 80 years of age suggest that azacitidine is effective even in older patients 
displaying a compromised performance status. Transfusion independence, impro-
vement of quality of life as well as relief of symptoms can be achieved with this 
Table 3. Revised International Prognostic Scoring System (IPSS-R)
Greenberg et al. Blood 2012; 120(12): 2454-65.
treatment option. It’s use is recommended in fit as well as in frail patients and might 
even benefit a minor portion of unfit patients. For the majority of unfit patients 
however, merely best supportive care, including transfusions, and palliation remain 
suitable options. 
1.7.5 Multiple myeloma
Although 5-year relative survival for patients younger than 65 improved in recent 
years, in older people little improvement was seen with 5-year overall survival rates 
of 22.7% in patients 75 years and over (106). Treatment should be initiated in all pa-
tients with symptomatic MM. For fit patients, induction followed by high-dose the-
rapy with autologous stem cell transplantation (ASCT) is the standard treatment. 
No randomized trials on the efficacy of ASCT in older patients are currently availa-
ble. Although some cohort studies have found a lower progression free survival 
(PFS) and OS for older patients, most studies found no difference between younger 
and older patients. However, to date no formal criteria exist as to which older adults 
are eligible for ASCT (107).
In older patients in a non-transplant setting oral combinations of melphalan and 
prednisone plus novel agents (thalidomide, bortezomib) are considered standard 
of care. In patients with clinical neuropathy, precluding the use of thalidomide or 
bortezomib, a combination of bendamustine plus prednisone can be used (108). A 
recent analysis showed that, along with the development of newer therapies, a 
significant improvement was seen in OS, especially in the older age group, reflecting 
the increased use of these novel agents also in older patients (109). Unfortunately, 
these standard schedules induce a high rate of grade 3-4 non-haematological ad-
verse events (AE). In a recent study 869 newly diagnosed multiple myeloma patients 
were divided into three categories (fit, frail, and unfit) based on age, functional 
status (ADL and IADL) and comorbidity. All patients participated in one of three 
multicenter prospective trials and treatment regimens did widely differ. Nevert-
heless, the 3-year OS was higher in fit patients compared to frail and unfit patients, 
while the risk of grade ≥ 3 non-haematological AE and the risk of drug discontinu-
ation were lower. (110). Due to a complete lack of further studies, no changes in dose 
and/or schedule are approved according to age or performance status to date (110). 
Treatment choices for frail and unfit patients therefore are still left at the discreti-
on of the treating physician. 
Summarizing, it may be said that more research is needed on the incorporation of 
CGA results into an individualized treatment plan and on how this treatment plan 
should look like for real life, frail older patients. Therefore every patient should at 
least be invited to participate in a clinical trial. Although limited in number, the abo-
ve-mentioned studies make it clear that older patients can be enrolled in clinical 
studies. However, the period for inclusion needs to be longer and it might take more 
persuasiveness to convince patients and, particularly, family members.
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2. GENERAL STUDY PROTOCOL
2.1 Participants
Between July 2011 and October 2013 all patients, 70 years or older, with a new diag-
nosis of AML, intermediate or high grade MDS, MM or high grade NHL, referred to the 
haematology department of a university hospital, were asked to participate in the 
current study. Patients were recruited proactively: daily review of the list of patients, 
newly admitted to the hospital, daily review of the agenda for the outpatient clinic and 
close contacts with haematologists, head nurses and nurse specialists. The possibility 
that a potential candidate was not addressed, therefore seems unlikely. Overall 71 pa-
tients were included and 14 patients refused to participate. The four main reasons for 
refusal were 1) candidate himself fails to see the added value or considers it an extra 
burden, 2) family does not want the candidate to be overburdened, 3) candidate is sus-
picious towards signing an informed consent, and 4) one candidate considered himself 
not old enough for a “geriatric” evaluation. Fifty patients had at least one reassessment 
and 33 patients had 2 or more. Fourteen patients died before a first reassessment could 
take place (20%). At 6 months follow-up 17 (24%) patients had died, while at the end of 
the study, 3 years after first inclusion, 46 (65%) patients had died. Five patients drop-
ped out and 2 patients were lost to follow-up. All participants provided written consent. 
The study was approved by the local Ethics Committee.
2.2 Composition of the CGA
2.2.1 Activities of daily living 
ADL was assessed using the Katz index of activities of daily living (Katz ADL) (111). 
The Katz ADL is designed specifically to assess a patient’s ability to perform ADL 
activities independently. The index ranks adequacy of performance in six domains: 
bathing, dressing, toileting, transferring, continence, and feeding. If no supervision, 
direction, or personal assistance is required, then 1 point is given to that functional 
activity. If the client requires supervision, direction, personal assistance, or total 
care, then a 0 is assigned to that functional activity. A score of 6 indicates ADL in-
dependency. 
2.2.2 Instrumental activities of daily living 
IADL was assessed using the Lawton scale (appendix 2). The Lawton IADL scale, 
based on self-reporting, is validated in older people to assess independent living 
skills, at a given moment as well as over a certain period of time (112). There are 8 
domains of function measured: ability to use telephone, shopping, food preparation, 
housekeeping, laundry, mode of transportation, responsibility for own medications, 
and ability to handle finances. Each item is rated dichotomously (0=less able, 1=more 
able) according to the highest level of functioning in that category. Women were 
scored on all 8 areas of function; for men, the areas of food preparation, house-
keeping and laundering were excluded. A summary score ranges from 0 to 8 for 
women, and 0 through 5 for men. A score of 8 for women and 5 for men indicates 
IADL independency.
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2.2.3 Performance status
Performance status was assessed using the ECOG-PS (113). The ECOG-PS describes 
a patient’s level of functioning in terms of their ability to care for themselves, daily 
activity, and physical ability. It is also a way to track changes in a patient’s level of 
functioning as a result of treatment. The ECOG-PS defines 5 levels of functioning:
0: fully active, able to carry on all pre-disease performance without 
restriction
1: restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature, e.g., light house work, 
office work
2: ambulatory and capable of all selfcare but unable to carry out any work 
activities; up and about more than 50% of waking hours
3: capable of only limited selfcare; confined to bed or chair more than 50% 
of waking hours
4: completely disabled; cannot carry on any selfcare; totally confined to 
bed or chair
5: dead
2.2.4 Nutrition
The Mini Nutritional Assessment – short form (MNA-SF) is a simple, well-validated 
screening tool for malnutrition in older persons and is recommended for early de-
tection of risk for malnutrition (114). The MNA-SF incorporates three cut-off points 
for nutritional status, thus allowing the identification of those who are normally 
nourished (12 – 14), at risk for malnutrition (8 - 11), or malnourished (≤ 7). 
2.2.5 Mood
Mood was assessed using the 4-item geriatric depression scale (GDS-4) (115). The 
GDS-4 is easy and quick to perform with a high sensitivity and specificity. GDS-4 is 
of limited clinical value in monitoring the severity of the depressive episode but 
more useful in excluding depression. Each question has a yes/no answer, with the 
scoring dependent on the answer given. A cut-off of ≥ 2 indicates depression. 
2.2.6 Cognition
Cognition was assessed using the mini mental state examination (MMSE), one of the 
most widely used measures of cognitive function. It provides an objective, relative-
ly brief, and inexpensive preliminary evaluation of cognitive status. The MMSE has 
a maximum score of 30 points, with different domains assessed: orientation to time 
and place, registration of 3 words, attention and calculation, recall of 3 words, lan-
guage, and visual construction. A score of < 24 was considered abnormal (116).
2.2.7 Falls
Falls history is one of the strongest predictors of future falling with a relative risk 
found to be 3.0 compared to non-fallers (117). Therefore, falls history was assessed 
using the question “have you fallen in the last year” or, in case of reassessment, 
“have you fallen since the previous evaluation”.
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2.2.8 Comorbidity
Comorbidity was assessed using the CIRS-G (appendix 1) (33). It classes comorbidi-
ties by organ system affected (14 organ systems), and rates them according to their 
severity from 0 to 4 (grade 1: mild problem, grade 2: problem of moderate severity 
requiring active therapy, grade 3: severe or constant disability, grade 4: extremely 
severe or urgent clinical problem), hereby taking into account total number as well 
as severity of comorbid conditions. Within each category, if two diseases are pre-
sent, the disease with the highest severity is counted. We summarized as the num-
ber of grade 1-2 and grade 3-4 diseases. 
2.2.9 Quality of life
Quality of life was assessed using the Functional Assessment of Cancer Therapy 
– General (FACT-G) (118). The FACT-G has 27 questions, each of which is answered 
using a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). Questions 
measure the patients’ health state over the last 7 days in four subscales: physical 
well-being, social/family well-being, emotional well-being, and functional well-being.
2.3 Methods
Main aim of this observational, monocentric study was to explore the added value 
of a CGA in older patients with haematological malignancies. Patients willing to 
participate were included after providing a written informed consent. All patients 
were assessed before start of therapy, 2 to 4 months later depending on the tre-
atment schedule, and once again 6 months after inclusion. During assessment all 
questionnaires stated above were completed. In addition some questions were 
asked concerning social framework and sensory impairment. Our final reference 
CGA consisted of a set of six questionnaires: ADL, IADL, GDS-4, MMSE, MNA-SF and 
any falls in the previous year.
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3. AIM OF THIS RESEARCH AND CHAPTER OVERVIEW
A significant increase has been seen in the number of older patients with cancer 
due to population ageing. One of the main challenges of treating older patients with 
cancer is to assess whether the expected benefits of treatment are superior to the 
risks in a population with decreased life expectancy and decreased tolerance to 
stress. In recent years research has mainly focused on solid tumours. The overall 
aim of this research was to explore whether in patients with haematologic malig-
nancies a geriatric approach and the use of a comprehensive geriatric assessment 
might prove worthwhile in the selection of patients with a geriatric profile, in the 
detection of geriatric syndromes and in the prediction of patient outcomes. 
In geriatric oncology, evidence suggests that a geriatric assessment identifies pre-
viously unknown geriatric problems in an individual. In haematology on the other 
hand, literature on the use of a CGA is scarce. In Chapter 2, the results of a geriatric 
assessment in older patients with a haematological malignancy are presented with 
focus on malnutrition and medication management in patients with polypharmacy. 
Furthermore their importance for this group of patients will be discussed.
This thesis will not only focus on the detection of geriatric syndromes, but also on 
a correct selection of patients with a geriatric profile, as the administration of a 
CGA is time- and staff-consuming. Therefore a two-step approach is proposed with 
the use of a screening tool to identify those patients that subsequently would be-
nefit most from a CGA. Two different screening tools were evaluated. In Chapter 3 
the performance of the G8 questionnaire as a screening tool for frailty in older pa-
tients with aggressive haematological malignancies is tested. Additional informa-
tion is provided on the composition of a CGA, and more specifically on the relation 
between CGA and comorbidity. In Chapter 4, hand grip strength (HGS) is studied as 
a screening tool to detect frailty. Frailty is, among other things, characterized by a 
loss of skeletal muscle mass and strength (sarcopenia). Hand grip dynamometry is 
a valid and reliable tool to represent total body muscle strength. In addition, the 
prognostic value of HGS in patients with haematological malignancies is tested. 
Finally, in Chapter 5, a summary is given of the main findings of the thesis, together 
with general concluding remarks.
An overview of the different studies, and the main research questions are descri-
bed in table 4. 
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Paper Focus Main research questions
Paper 1
(Chapter 2)
Nutritional assessment 
using the MNA-SF, in older 
patients with high-grade 
haematological 
malignancies
How is the baseline nutritional status ?
What is the prevalence of malnutrition and risk  
for malnutrition?
Which MNA-SF items are most frequently 
involved?
Can BMI be used as a marker for nutritional 
problems ?
Is nutritional screening by MNA-SF useful?
Paper 2
(Chapter 2)
Polypharmacy and 
functional autonomy in 
medication management
How does IADL independence evolve after start  
of therapy?
Is there a change in independent medication 
management after start of therapy?
Is there a correlation between independent 
medication management and polypharmacy?
Is there a correlation between independent medica-
tion management and drug regimen complexity?
Which medication regimen characteristics 
contribute to regimen complexity?
Paper 3
(Chapter 3)
G8 as a screening tool  
for CGA
What is the prevalence of an impaired score  
for the various CGA questionnaires?
Can the G8 be validated as a screening tool to 
identify patients who would benefit from a CGA 
before start of therapy?
What is the optimal cut-off point for likelihood  
of abnormal CGA?
Paper 4
(Chapter 4)
Hand grip strength as a 
screening tool for CGA
How is the muscle function at diagnosis?
Can HGS be validated as a screening tool to 
identify patients who would benefit from a CGA 
before start of therapy?
What are the optimal cut-of points for likelihood  
of abnormal CGA for both men and women?
Is there an association between HGS and 
concurrent abnormal G8?
Is there an association between HGS and 
subsequent adverse events during therapy?
Is there an association between HGS and 
subsequent 6-month mortality?
MNA-SF = mini nutritional assessment – short form, BMI = body mass index,  
IADL = instrumental activities of daily living, CGA = comprehensive geriatric assessment,  
HGS = hand grip strength
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Table 4. Main research questions
Appendix 1. CIRS-G scoring sheet.
Miller et al. Psychiatry Research 1992; 41(3): 237-48
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Appendix 2. Lawton IADL scale.
Lawton et al. Gerontologist 1969; 9(3): 179-186
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EVALUATION OF THE NUTRITIONAL STATUS IN OLDER 
PATIENTS WITH AGGRESSIVE HAEMATOLOGICAL 
MALIGNANCIES USING THE MNA-SF
A. Velghe, L. Noens, R. Demuynck, S. De Buyser, M. Petrovic. 
Eur Geriatr Med 2014; 5(4): 258-260. http://dx.doi.org/10.1016/j.eurger.2014.03.003
ABSTRACT
Background: Malnutrition is common both after the age of 70 and in many types 
of cancer, being responsible for poor quality of life, poor treatment response and 
a shorter survival time. Patients with haematological malignancies face specific 
challenges regarding nutrition because of intensive treatments they endure. Early 
detection of nutritional problems is important to allow interventions. 
Objectives: to assess the nutritional status of a group of older patients with ag-
gressive haematological malignancies before the onset of systemic therapy using 
the MNA-SF. 
Setting: the haematology department of a university hospital
Participants: patients, ≥ 70 years, with newly diagnosed aggressive haematologi-
cal malignancies
Methods: observational single centre study. Patients were screened for malnutri-
tion before and two months after start of therapy using the Mini Nutritional As-
sessment Short Form (MNA-SF). 
Results: Seventy patients were included. Mean age was 77.4 ± 4.7 years (range 
70.0-91.0). At baseline, 20% (CI95 = 11-31%) were malnourished and 61% (CI95 = 49-
73%) were at risk for malnutrition. Recent weight loss and declined food intake were 
the most recorded MNA-SF parameters. Mean Body Mass Index (BMI) was 26.3 ± 
4.1 (range 19.8 - 41.1) and 41% (n=29) of patients had a BMI < 25. 
Conclusions: Using the MNA-SF, most of older patients with an aggressive haema-
tological malignancy are at risk for malnutrition. Therefore, nutritional assessment 
with individualized dietary advice and follow-up during treatment should be re-
commended as an integrated part of the treatment plan.
INTRODUCTION
Malnutrition is frequent after 70 years of age due to inadequate dietary intake and 
particularly protein intake. Causes of poor nutritional status in older people are 
multi-factorial and include the physiological, psychological and social changes as-
sociated with aging which affect food intake and body weight (1). Nutritional scree-
ning aims to identify, in a simple and non-invasive way, those patients who may be 
at risk for malnutrition (2).
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Studies in community-dwelling older persons, using the Mini Nutritional Assess-
ment (MNA), show that between 0 and 2% are malnourished and between 15% and 
44% are at risk for malnutrition (3). The prevalence of malnutrition amongst patients 
with cancer depends on the tumour type, location, stage and treatment. However, 
this prevalence has not been well established in the specific case of onco-haema-
tological patients. Patients with haematological malignancies face specific challen-
ges associated with eating and nutrition because of the intensive and aggressive 
treatments they endure (4; 5).
In this study we wanted to assess the nutritional status of a group of older patients 
with aggressive haematological malignancies using the MNA-SF. 
MATERIALS AND METHODS
Patients 
Between July 2011 and October 2013 all patients, 70 years or older, with a new di-
agnosis of Acute Myeloid Leukaemia (AML), intermediate or high grade Myelo-
dysplastic Syndrome (MDS), Multiple Myeloma (MM) or high grade Non Hodgkin 
Lymphoma (NHL), referred to the haematology department of a university hospital, 
were asked to participate in this observational monocentric study. All participants 
provided written consent. The study was approved by the local Ethics Committee.
Nutritional screening
Before the start of therapy all patients were screened for malnutrition by means 
of the MNA Short Form (MNA-SF). Nutritional screening was repeated two to four 
months later, depending on the treatment schedule. The MNA-SF is a simple, well-va-
lidated screening tool for malnutrition in older persons and is recommended for 
early detection of risk for malnutrition (3). The MNA-SF incorporates three cut-off 
points for nutritional status, thus allowing the identification of those who are nor-
mally nourished (≥ 12), at risk for malnutrition (8 - 11), or malnourished (≤ 7). 
Statistical methods
Descriptive analyses were performed to summarize patient and treatment charac-
teristics. Continuous variables were expressed as mean ± standard deviation (SD) 
(range). Countable variables were presented as absolute number (n) and percenta-
ge (%) of the study population. Additionally 95% confidence intervals (CI95) were 
computed. All analyses were performed in Medcalc® Version 12.7.0.0 (Medcalc 
Software bvba).
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Table 1. Baseline characteristics of the patients
Characteristics
Sex, n (%)
Male 36 (51)
Female 34 (49)
Age (years), n (%)
<75 22 (31)
75-80 28 (40)
>80 20 (29)
ECOG performance status, n (%)
0-1 46 (66)
2-4 24 (34)
Diagnosis, n (%)
AML 22 (31)
NHL 28 (40)
MDS 11 (16)
MM 9 (13)
Number of comorbidities, mean (range)
 Grade 1 – 2 £ 3 (0 – 8)
 Grade 3 – 4 £ 2 (1 – 5)
Weight (kg), mean (range) 73.3 (50.0 – 117.0)
BMI, mean (range) 26.3 ± 4.1 (19,8 – 41,1)
> 3 medications, n (%) 46 (66)
Patients with MMSE < 24, n (%) 3 (4.8)
Patients dependent in IADL, n (%) 29 (41.4)
ECOG = Eastern Cooperative Oncology Group, AML = Acute Myeloid Leukaemia, NHL = Non-Hodgkin 
Lymphoma, MDS = Myelodysplastic Syndrome, MM = Multiple Myeloma, BMI = Body Mass Index
£ grade 1: mild problem, grade 2: problem of moderate severity requiring active therapy, grade 3: se-
vere or constant disability, grade 4: extremely severe or urgent clinical problem
MMSE = mini mental state examination
IADL = instrumental activities of daily living
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RESULTS
Seventy patients were included. Mean age was 77.4 ± 4.7 years (range 70.0-91.0). 
Baseline patient characteristics are summarized in table 1.
At baseline, 20% (CI95 = 11-31%) of the patients (n=14), assessed by MNA-SF, were 
malnourished and 61% (CI95 = 49-73%) of the patients (n=43) were at risk for mal-
nutrition. Recent weight loss (63%, n=44) and declined food intake (49%, n=34) were 
the most recorded MNA-SF parameters. Mean BMI was 26.3 ± 4.1 (range 19.8 – 41.1) 
and 41% (n=29) of all patients had a BMI < 25.
DISCUSSION
Our first research question addressed the baseline nutritional status of a group of 
older patients with aggressive haematological malignancies. Older people who are 
already malnourished at home may additionally be at a disadvantage in the pre-
sence of cancer. Using the MNA-SF, we found a high percentage of individuals at 
risk for malnutrition in this group of older onco-haematological patients. Only few 
studies have been conducted on the prevalence of malnutrition or risk for malnutri-
tion in older patients with haematological diseases (6; 7). Bauduer et al. randomly 
tested 120 patients, treated for miscellaneous blood disorders, the day of their 
admission to either the out- or inpatient clinic, by means of the MNA. They found 
a prevalence of malnutrition of 13%. Our results with 20% of malnourished patients 
are in concordance with the findings of the aforementioned study. In contrast, about 
50% of their patients were free of nutritional problems compared to 19% in our 
patient group. However, Bauduer et al. included patients with non-malignant hae-
matological problems and indolent malignancies. We included only patients with 
an aggressive haematological malignancy. Moreover, mean age in our study popu-
lation was higher (74.6 years vs. 77.4 years ) (6).
Malnutrition in older patients with cancer is associated with negative outcomes 
including increased morbidity, poor quality of life, poor response to and tolerance 
of chemotherapy, a shorter survival time and increased healthcare costs (2). In our 
study, recent weight loss and diminished food intake were the most prevalent MNA-
SF items indicating (risk for) malnutrition. In general, in patients with cancer, base-
line weight loss is associated with poorer survival, reduced likelihood of complete 
response to treatment and poorer quality of life (8). Tubiana et al. have shown that 
weight loss greater than 10% of body weight in the previous six months was asso-
ciated with a shorter survival in patients with Hodgkin’s Disease (9). In a large study 
of 3047 patients enrolled in 12 chemotherapy protocols of the Eastern Cooperative 
Oncology Group, median survival was significantly shorter for the patients with 
weight loss. Among haematological malignancies, this observation was true for 
NHL (favourable as well as non-favourable) but not for AML cases. In these AML 
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cases survival was very short in all patients regardless of weight loss. In these pa-
tients other factors were more important than weight loss in determining survival. 
In patients with unfavourable NHL the median survival was approximately twice 
as long in those with no weight loss as in those with weight loss. Moreover, in this 
study was shown that even small amounts of weight loss (less than 5 percent of 
body weight) may significantly worse prognosis. Patients with weight loss respond 
poorly to chemotherapy and experience increased toxicity. In addition, reduced 
functional capacity and performance status contribute to a lower quality of life (10). 
In addition, qualitative research among haematological patients indicated that is-
sues surrounding food and eating are considered to be of great significance both 
for patients and for their caregivers. The significance of food is not seen purely in 
relation to its nutritional value, but as an important quality of life issue (5).
Once patients are identified through screening to be at moderate or high risk, a 
comprehensive nutritional assessment follows. A nutritional assessment incorpo-
rates anthropometric measurements, laboratory tests, medical history, clinical 
indicators, current and planned medications, a detailed dietary history and a func-
tional assessment including physical activity (11). An in-depth nutritional evaluation 
is time-consuming and requires a skilled dietician, preferably with an expertise in 
oncology. Therefore nutritional assessment might be difficult to implement in many 
settings. However, 81% of our patients already scored positive on MNA-SF at the 
time of diagnosis. Therefore systematic screening in older patients with an aggres-
sive haematological malignancy, using the MNA-SF, does not seem to provide an 
added value since nutritional assessment would be necessary in a large majority 
of the patients. Consequently, in this group of patients, nutritional assessment 
should be considered as a first step approach. Gómez-Candela et al. recommend 
nutritional assessment instead of nutritional screening as a first step approach for 
those onco-haematological diagnoses where anti-neoplastic therapy is associated 
with a moderate to high nutritional risk (4). As we selected patients facing an ag-
gressive anticancer therapy, our findings are in line with these recommendations.
In our study, recent weight loss and declined food intake were the most prevalent 
MNA-SF items indicating (risk for) malnutrition. In routine clinical practice BMI is 
still often used as a measure for malnutrition. Only 41% of our patients had a BMI 
< 25. A low BMI indicates chronic malnutrition, whereas unintentional weight loss 
indicates a more acute deterioration of nutritional status as can be expected in 
patients with an aggressive malignancy (12). In high grade malignancies, nutritional 
screening based on BMI will result in a delay in the start of nutritional support and 
thereby endanger patient’s outcome.
To our knowledge, this is the first report on the baseline nutritional status in a group 
of older patients with a diagnosis of an aggressive haematological malignancy. Ba-
sed on the MNA-SF, nutritional risk appears high in older patients, apart from an-
ti-neoplastic therapy. Therefore, nutritional assessment with individualized dietary 
advice and follow-up during treatment is preferable. In order to overcome a lack of 
attention from hospital staff, nutritional assessment performed by a dietician, pre-
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ferably with experience in the field of haematology, needs to become an integrated 
part of the treatment plan of a patient. 
Our study had several limitations. First, there might have been a referral bias. Only 
41% (n=29) of our patients was dependent in Instrumental Activities of Daily Living 
(IADL) and only 4% (n=3) of them had an abnormal Mini Mental State Examination 
(MMSE) score (< 24) at baseline. This is considerably less than what can be found in 
the literature (13). As a tertiary centre, a significant number of patients are referred 
from other hospitals. Referring physicians may have considered older patients with 
physical, cognitive or emotional problems no longer candidates for aggressive the-
rapy. On the other hand, the risk of being malnourished would be even higher when 
these patients were included. Second, the sample size was relatively small due to 
the patients’ fragile condition, possible referral bias and the reluctance to partici-
pate in a clinical study. The latter improved once geriatric evaluation was introdu-
ced as “standard of care” for all haematological patients above the age of 70. Third, 
one can argue that some items of the MNA short form scale can be altered by the 
haematological disease more than by malnutrition, since the MNA-SF has not been 
validated to detect malnutrition in haematological patients. Lastly, at this moment, 
we have no information on the impact of nutritional assessment as a first step ap-
proach on the outcome of our patients or their quality of life. This will be the subject 
of a future study.
In summary, these results demonstrate that most of the older patients with a hae-
matological malignancy facing aggressive therapy are malnourished or at risk for 
malnutrition. Therefore, we recommend nutritional assessment by a dietician with 
individualized dietary advice and follow-up during treatment to become an inte-
grated part of the treatment plan in this group of older patients.
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LOSS OF FUNCTIONAL AUTONOMY IN MEDICATION 
MANAGEMENT AFTER START OF THERAPY IN OLDER PATIENTS 
WITH HAEMATOLOGICAL MALIGNANCIES
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ABSTRACT
Purpose: Guidelines on older cancer patients recommend a comprehensive geriatric 
assessment, preferably including an item on medication management since cancer 
treatment further increases risks of polypharmacy. So far, little attention is given 
to non-adherence due to functional changes. We aimed to assess autonomy in drug 
self-administration after start-up of therapy in older patients with haematological 
malignancies. In case of inadequate compliance, we tried to identify the causes.
Methods: Longitudinal single centre cohort study in patients ≥ 70 years. Patients 
underwent a geriatric evaluation before and two months after start of therapy. 
Medication was registered both times.
Results: Sixty-two patients, median age 77 years, were included. At baseline 49 
patients (79%) took their long-term medication independently. Independent medi-
cation management was significantly higher in patients taking <5 medications (93.7% 
vs. 63.3%, p < 0.005). After start of therapy, polypharmacy rates increased from 
48.3% to 98.3% (n=61) while 55.6% of the initially independent patients became 
dependent for medication management. The median increase in the number of 
medications was significantly higher in dependent patients (6 vs. 4.5, p<0.05). Mul-
tiple daily doses (80%, n=50), varying doses (59.7%, n=37) and medication splitting 
(45.3%, n=27) further contributed to regimen complexity. Unlike results at baseline, 
no correlations were found between autonomy in medication management and 
medication regimen two months after therapy start-up.
Conclusion: Haematological patients have to face a wide turnover of chemo drugs 
to treat malignancies. A considerable number of them require assistance in drug 
administration during time: attention has to be paid to patient compliance, and im-
proving it, highlighting the challenges of an ambulatory setting.
INTRODUCTION
The incidence rates of haematological malignancies increase steadily with age. Tre-
ating older patients suffering from aggressive haematological malignancies is beco-
ming a challenging task for all caregivers involved, since the heterogeneity of the 
aging process is characterised by marked variability in the rate of functional loss, 
both between and within individuals (1; 2). However, chronological age does not reflect 
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these individual differences and therefore is not a good predictor of remaining func-
tional reserves or life expectancy. Guidelines on older cancer patients, such as those 
from the National Comprehensive Cancer Network (NCCN) or the International So-
ciety of Geriatric Oncology (SIOG), recommend the use of a Comprehensive Geriatric 
Assessment (CGA) as a multidimensional, interdisciplinary diagnostic process focusing 
on determining a frail older person’s physical, psychological and functional capabili-
ties (3-5). Although no gold standard exists, there is consensus that the CGA should 
include functional, cognitive, emotional and psychosocial status as well as the aspects 
of nutrition, mobility and polypharmacy, in addition to comorbidity assessment (6).
Polypharmacy schedules involving five or more drugs, with increased drug regimen 
complexity and risk of adverse drug reactions (ADRs), drug-drug interactions (DDI), 
inappropriate self-medication and poor drug adherence are an area of concern, espe-
cially in older patients. In the older cancer cohort, chemotherapy and supportive drugs 
to prevent side-effects or treat symptoms additionally increase the risks and compli-
cations of polypharmacy. Guidelines recommend reviewing the number and the type 
of medications in all patients and, in case of more than three medications, looking for 
duplications, interactions, and non-adherence (6). Studies on the optimization of geria-
tric pharmacotherapy focus most commonly on pharmacological outcomes and prog-
nosis, ADRs and potentially inappropriate medication. However, little attention has so 
far been paid to (unintentional) non-adherence due to functional problems or changes, 
despite the well-known fact that older patients experience a gradual decline in their 
cognitive and functional abilities which are required for medication management.
Although a CGA, as a multidimensional diagnostic process, generally includes an 
evaluation of functional, cognitive, emotional and psychosocial status as well as 
the aspects of nutrition, mobility and polypharmacy, the assessment tools included 
may differ widely. Nevertheless, most CGAs currently used in studies do not inclu-
de an item on medication management, except for one item in the Lawton Instru-
mental Activities of Daily Living Scale (IADL) (7). Apart from “taking medication as 
prescribed”, seven more independent living skills are assessed. For each of these 
skills one can identify the overall social and autonomous patient function at time 
0 and whether an improvement or deterioration follows upon it.
In our study population, based on IADL assessment during treatment, we aimed to 
assess autonomy in medication management after the start of therapy in older 
patients with a haematological malignancy. Additionally, in cases of deterioration, 
we aimed to search for predetermining factors.
MATERIALS AND METHODS
Patients 
This was a longitudinal single centre cohort study. All patients aged 70 years or 
older with a new diagnosis of Acute Myeloid Leukaemia (AML), intermediate or high 
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grade Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) or high grade Non 
Hodgkin Lymphoma (NHL) who were referred to the haematology department of 
a tertiary hospital between June 2011 and January 2013, were asked to participa-
te in the current study. All participants provided written consent. The study was 
approved by the local Ethics Committee.
Geriatric evaluation
Before chemotherapy administration all patients underwent Comprehensive Ge-
riatric Assessment (CGA) by a member of the geriatric team. Since no gold standard 
exists, our CGA consisted of a set of six questionnaires, i.e. Activities of Daily Living 
(ADL) (8), Instrumental Activities of Daily Living (IADL) (7), 4-item Geriatric Depres-
sion Scale (GDS-4) (9), Mini Mental State Examination (MMSE) (10), Mini Nutritional 
Assessment – Short Form (MNA-SF)(11), and any falls in the previous year. Comor-
bidity was assessed using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). 
In addition, patients were asked some questions on social and financial items. This 
geriatric evaluation was repeated two to four months later, depending on the tre-
atment schedule. 
The Lawton IADL Scale, based on self-reporting, is validated in older people to as-
sess independent living skills, at a given moment as well as over a certain period of 
time. There are 8 domains of function measured: ability to use telephone, shopping, 
food preparation, housekeeping, laundry, mode of transportation, responsibility 
for own medications, and ability to handle finances. Each item is rated dichoto-
mously (0=less able, 1=more able) according to the highest level of functioning in 
that category. Specifically for medication intake patients score 1 point only when 
they are able to manage their medication completely independently. If someone 
else is preparing the medication in advance, a patient is scoring 0 points, even if he/
she is taking his/her pills autonomously throughout the day.
Medication review
Habitual medication was registered on entrance in the study and two months later. 
Medication lists, as written down in the letter to the treating general practitioner, 
were reviewed shortly after the start of therapy. Polypharmacy was defined as ≥ 
5 medications. In the initial design of the study (and thus before the results of IADL 
were available) eye-drops, mouth rinses and topical creams were not taken into 
consideration as these products were unlikely to produce a systemic effect. Neither 
did we count “as needed” medication as it was not known whether or not the pa-
tient was taking this medication.
Statistical methods
Descriptive analyses were performed to describe patients’ characteristics and geri-
atric evaluation results. Continuous variables were expressed as median and range. 
Countable variables were presented as absolute number (n) and percentage (%) of the 
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study population. To assess differences between categories, the Pearson chi-square 
test was used. Univariate logistic regression analysis was used to identify medication 
regimen characteristics associated with (in)dependent medication management. All 
analyses were performed in Medcalc® Version 12.7.0.0 (Medcalc Software bvba).
RESULTS
Sixty two patients were included in the study. Baseline characteristics are presen-
ted in table 1. Median age was 77 years (range 70-91). The results of the geriatric 
evaluation as well as changes in IADL over time are presented in table 2. At baseline 
49 patients (79%) took their chronic medication without any assistance. Independent 
medication management was significantly higher in the group of patients taking less 
than 5 medications (93.8% vs. 63,3%, p < 0.005).Two months after the start of the-
rapy 8 patients died and 6 were lost to follow-up. Of the formerly independent pa-
tients, 55.6% (20 of the remaining 36) needed assistance for their medication.
Table 1. Baseline characteristics of the patients (N=62)
Sex, n (%)
Male 30 (48.4)
Female 32 (51.6)
Age (years), n (%)
<75 19 (30.6)
75-80 26 (41.9)
>80 17 (27.4)
Diagnosis, n (%)
Acute Myeloid Leukaemia 16 (25.8)
High Grade Lymphoma 24 (38.7)
Myelodysplastic Syndrome 12 (19.4)
Multiple Myeloma 7 (11.3)
Number of comorbidities, median (range)
Grade 1 - 2 £ 4 (0 - 9)
Grade 3 - 4 $, £ 1 (0 - 4)
$ current haematological diagnosis not included
£ grade 1: mild problem, grade 2: problem of moderate severity requiring active therapy, grade 3: 
severe or constant disability, grade 4: extremely severe or urgent clinical problem
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Table 2. Results of the geriatric evaluation (N=62)
Living status, n (%)
Alone 24 (38.7)
Living with spouse 33 (53.2)
Living with family member (other than spouse) 4 (6.5)
Long term care facility 1 (1.6)
“Do you expect financial problems because of your disease?”, n (%)
Yes 4 (6.5)
No 58 (93.5)
Patients with MMSE £ < 24, n (%) 3 (4.8)
Number of patients (N=46) with decline from baseline in individual IADL-items, n (%)
Ability to use telephone 1 (2.2)
Shopping 13 (43.3)
Food preparation 9 (33.3)
Housekeeping 12 (33.3)
Laundry 13 (46.4)
Mode of transportation 12 (41.4)
Responsibility for own medications 20 (55.6)
Ability to handle finances 2 (4.4)
£ Mini Mental State Examination
Polypharmacy was being administered in 48.4% of patients (n =30) at the time of 
diagnosis and increased to 98.3% (n=61) during follow-up. Likewise, the intake in-
creased from a median of 4 (0-10) medications to a median of 9 (4-16) medications 
and 11 (4-22) pills a day. In patients dependent for medication management at ba-
seline, the median increase in the number of medications was significantly higher 
than in their independent counterparts (6 vs. 4.5, p<0.05). The medication regimen 
characteristics are presented in table 3. Unlike results at baseline, no correlations 
were found between autonomy in medication management and medication regi-
men characteristics two months after the start of therapy. 
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Table 3. Medication and medication regimen characteristics (N=62)
Patients with at least 1 demanding dosage form, n (%) 25 (40.3)
Tablet splitting, n (%) 27 (43.5)
≥ 1 drug with multiple doses per day, n (%) 50 (80.6)
≥ 1 drug with different dosages depending on time of week, n (%) 37 (59.7)
≥ 12 drug administrations per day, n (%) 28 (45.1)
≥ 3 drugs with different dosing intervals, n (%) 18 (29.0)
N° of drug prescriptions, n (%) :
 Cardiovascular agents 151 (28.6)
 Supportive agents 152 (28.8)
DISCUSSION
According to the guidelines, every older patient with cancer should undergo a ge-
riatric assessment (4;5). In our study population, the assessment was repeated two 
months after the start of therapy and compared with baseline evaluation. Two main 
aims of our study were to assess autonomy in medication management after the 
start of therapy and, in cases of deterioration, to search for predetermining factors.
At baseline 21% of patients needed assistance with medication intake, which is 
comparable to what we found in the literature (12;13). Independent medication ma-
nagement was significantly higher in the group of patients taking less than 5 me-
dications (p<0.005). Two months after the start of therapy, rates of polypharmacy, 
and hence drug regimen complexity, increased from 48% to 98% and from a medi-
an of 4 to a median of 9 prescription drugs, while more than a half of the remaining 
and initially independent patients became dependent for medication intake. Mo-
reover, in patients dependent for medication management at baseline, the median 
increase in the number of medications was significantly higher (p<0.05).
Drug regimen complexity has generally been defined as the number of medications 
and daily administrations of distinct drugs (14-16). This definition does not take into ac-
count other regimen characteristics that might contribute to drug regimen complexi-
ty: tablet splitting (13;16-18), the route of drug administration (17;19;20), different doses throug-
hout the day or week (17;19;20), drugs with multiple doses per day (15) or with different 
dosing intervals (14;20), all of which were present in a considerable percentage of medi-
cation lists. Drug regimen complexity is related to patient non-adherence but also to 
medication errors, adverse drug events and therapeutic failure (14;20). 
With regard to the second aim, in contrast with the results at baseline, we could no 
longer find a correlation between polypharmacy and autonomy in medication ma-
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nagement neither could we find a correlation between regimen complexity and (in)
dependence in medication intake. 
The most plausible explanation for this lack of statistical significance is the relati-
vely small sample size. Furthermore the binary coding of IADL-items does not allow 
one to differentiate between degrees of dependence: patients already dependent 
for medication, albeit just needing pills to be prepared once a week by a caregiver 
using a dose administration aid, will keep the same score even if, after two months, 
the patient has moved to a nursing home where his medication is brought to him 
at set times. 
As the IADL-item on “responsibility for own medications” purely addresses the 
practical aspects of medication management and provides no information as to the 
cause of the incapacity, plausible explanations other than regimen complexity were 
considered. General weakness, as a result of their illness and treatment, might be 
one. This is, however, doubtful if we look at other IADL-domains like housekeeping 
and food preparation, both physically demanding, where the percentage of patients 
with a decline proves less prominent. Cognitive decline is also unlikely as MMSE-sco-
res remained stable over time and were, except for 3 patients, within normal range. 
We therefore believe that the loss of autonomy for medication management is lar-
gely related to regimen complexity.
For patients living together medication management is often taken over by the 
spouse. Spouses, in most cases, are of the same age as their partner and the same 
evaluation might apply to the spouse as well. However, patients without a spouse 
might be left on their own. Clinicians often fail to predict correctly a patient’s cog-
nitive and/or functional capacity to manage medication (21) while patients might not 
report potential problems unless they’re specifically asked, for example in the cour-
se of a geriatric evaluation. No studies are available addressing the issue of self-me-
dication becoming unsafe and when to switch the medication management to an 
informal or formal caregiver (21).
The findings of this study might make health care professionals in charge of older 
patients with haematological malignancies more aware of the impact of polyphar-
macy, frequent regimen changes and drug regimen complexity during treatment, 
and draw their attention to some unmet needs. Multidisciplinary teams including 
pharmacists and well-trained nurses or nurse specialists are already involved in 
medication reconciliation and patient education in order to improve medication 
adherence (21;22). However, in older patients with cancer, at least during treatment, 
increased emphasis should be placed on direct observation of medication handling 
for both, patient and spouse, preferentially using a patient’s own medication (23;24). 
In an era where health care systems are asked to establish quality indicators with 
an emphasis on appropriate medication use, our present findings call for develop-
ment of a specific “self-administration of medications program” for older ambula-
tory cancer patients based on information, education and medication preparation 
under nursing supervision. 
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Our study had several limitations. First, the study was a single-centre study with 
a small sample size. Second, we did not take into account eye-drops, mouthwash 
and topical creams, or prescriptions for “as needed” medication. Although non-oral 
medications are probably less related to adverse drug reactions, they certainly 
contribute to the complexity of medication regimens. Inclusion of these medicati-
ons would additionally have emphasized the magnitude of the problem. Third, we 
have no information as to the cause of the incapacity, but whatever the reason 
might be, the need for an individual appraisal of medication management remains. 
Finally, the appropriateness and quality of prescribing was not assessed.
In conclusion, haematological patients are subject to extensive changes in their 
medication regimen at the start of therapy. A considerable number of these pa-
tients show loss of independence for medication management. Future research, 
based on a larger study population, and future care pathways should focus on de-
tection and remediation, taking particularly into account the challenges of an am-
bulatory setting.
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ABSTRACT
Background: Incidence rates of haematological malignancies increase with age. In 
these older cancer patients, important information may be missed without a Com-
prehensive Geriatric Assessment (CGA). A validated screening instrument is needed 
to identify those patients for whom a CGA would be beneficial. The G8 has recent-
ly been validated as a screening tool for older cancer patients in need of a CGA.
Objectives: To test the performance of the G8 screening tool in older patients with ag-
gressive haematological malignancies to identify those who would benefit from a CGA.
Methods: Cross-sectional study of patients ≥ 70 years with a recently diagnosed hae-
matological malignancy. G8, CGA (including six questionnaires) and Cumulative Illness 
Rating Scale for Geriatrics (CIRS-G) were completed in each patient. The CGA was 
considered abnormal when at least one questionnaire showed an impaired score. 
Results: Fifty patients with median age of 76 years were included; 88% (N=44) had 
an abnormal CGA. ROC curve analyses revealed a G8 score ≤ 14 obtained a sensiti-
vity of 89% (95% CI 75-96) and a specificity of 100% (95% CI 54-100), suggesting an 
optimal cut-off point. AUC ± SE was 0.949 ± 0.030. Inclusion of comorbidity in the 
CGA did not change the performance of the G8 (0.943 ± 0.034; P = 0.895). 
Conclusion: The G8 can be used as a valid screening tool in older patients with ag-
gressive haematological malignancies to identify those patients who would benefit 
from a CGA. Comorbidity should be assessed routinely and independently of the G8.
INTRODUCTION
Incidence rates of haematological malignancies increase steadily with age. Haema-
tological malignancies have some unique features such as frequent bone marrow 
involvement, rapid response to chemotherapy which might lead to remarkable 
functional improvement and, even in advanced stages, treatments offering good 
chances of long-term remission or cure (1). However, treating older patients with 
aggressive haematological malignancies is a challenging task for all those involved, 
since the heterogeneity of the aging process is characterised by marked variability 
in the rate of functional deterioration, both between and within individuals (2;3). The 
clinical implications include different tolerance to cancer and cancer treatment 
complications. Therefore, individualised management, tailored to differences in 
functional capacity, life expectancy, and social and economic support, is needed. 
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Over the years, extensive and robust evidence demonstrates that a Comprehensi-
ve Geriatric Assessment (CGA) improves outcomes (e.g. slower disability progres-
sion, a reduced fall risk, a lower rate of unplanned hospitalisation and nursing home 
admission) in older patients affected by multiple interdependent medical and so-
cial problems in different clinical settings (4). A CGA is a multidimensional, interdis-
ciplinary diagnostic process focused on determining a frail older person’s physical, 
psychological and functional capabilities in order to develop a co-ordinated and 
integrated plan for treatment and long-term follow-up (5). Evidence exists that im-
portant information may be missed if a CGA-based approach is not applied in older 
patients with cancer (4).
Since a CGA might be very time-consuming, the current challenge in oncology is to 
identify those unfit patients for whom the CGA would be most beneficial, justifying 
the use of a screening instrument (6).
The G8 tool has recently been validated as a screening tool in patients older than 
70 with cancer. Patients who screen abnormal with the G8 tool would benefit from 
a CGA, followed by a geriatric intervention when indicated (7).
The aim of this study was to test the performance of the G8 as a screening tool in 
older patients with aggressive haematological malignancies to identify who would 
benefit from a CGA.
MATERIALS AND METHODS
Patients 
This was a cross-sectional study. All patients aged 70 years or older with a new 
diagnosis of Acute Myeloid Leukaemia (AML), intermediate or high grade Myelo-
dysplastic Syndrome (MDS), Multiple Myeloma (MM) or high grade Non Hodgkin 
Lymphoma (NHL) who were referred to the haematology department of a tertiary 
hospital between June 2011 and January 2013, were asked to participate in the 
current study. All participants provided written consent. The study was approved 
by the local Ethical Committee.
G8 and CGA
The G8 screening tool (table 1) includes 8 items that yield a total patient score ran-
ging from 0 (heavily impaired) to 17 (no impairment). A cut-off score of 14 was used 
to detect frailty in older cancer patients (6) .
Since no golden standard exists, our CGA consisted of a set of six questionnaires, 
Activities of Daily Living (ADL) (8), Instrumental Activities of Daily Living (IADL) (9), 
4-item Geriatric Depression Scale (GDS-4) (10), Mini Mental State Examination (MMSE) 
(11), Mini Nutritional Assessment – Short Form (MNA-SF)(12), and any falls in the previ-
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ous year. A CGA was considered abnormal when a patient received an impaired sco-
re on at least one questionnaire. In addition to these questionnaires, comorbidity 
was evaluated using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) (13). 
In each patient, the G8, the CGA and the CIRS-G were completed by a member of 
the geriatric team before therapy was started. 
Statistical methods
Descriptive analyses were performed to describe patient and treatment characte-
ristics and geriatric assessment results. Quantitative continuous variables were 
described using mean and standard deviation (SD) for normal data or median and 
range otherwise. Countable variables were presented as absolute number (N) and 
percentage (%) of the study population. 
The performance of the G8 screening tool was evaluated using Receiver Operating 
Curve (ROC) analyses and the area under the ROC curve (AUC) ± standard error 
(SE). Sensitivity and specificity, with 95% confidence intervals (95% CI), were calcu-
lated at the G8 cut-off score ≤ 14. AUCs from obtained ROC curves were statistical-
ly compared by using a two-sided z-test.
A sample of six patients for each CGA outcome (normal/abnormal) will be required 
to detect a difference of 0.409 between the AUC under the null hypothesis of 0.500 
and an AUC under the alternative hypothesis of 0.909, assuming a power of 80% 
and a significance level of 5%. This number was based on the result of Pottel et al., 
who observed an AUC under the alternative hypothesis of 0.909 (14).
All analyses were performed in MedCalc® Version 12.7.0.0 (MedCalc Software Ltd).
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Table 1. G8 screening questionnaire (total score 0–17).
Score
Has food intake declined over the past 3 months owing to loss of appetite,  
digestive problems, chewing or swallowing difficulties?
Severe decrease 0
Moderate decrease 1
No decrease 2
Weight loss during the past 3 months
> 3 kg 0
Patient does not know 1
1 – 3 kg 2
No weight loss 3
Mobility
Bed or chair bound 0
Able to get out of bed/chair but does not go out 1
Goes out 2
Neuropsychological problems
Severe dementia or depression 0
Mild dementia or depression 1
No psychological disorders 2
BMI (kg/m²)
< 18.5 0
18.5 - < 21.0 1
21.0 - < 23.0 2
≥ 23.0 3
Takes more than three medications per day
Yes 0
No 1
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In comparison with other people of the same age,  
how does the patient consider his or her health status to be?
Not as good 0
Does not know 0,5
As good 1
Better 2
Age (years)
> 85 0
80-85 1
< 80 2
RESULTS
Patient and treatment characteristics and geriatric assessment results
Fifty patients were included in the study. Baseline characteristics are summarised 
in table 2. Median age was 76 years (range 70-87). Sixty-four percent of patients 
(N=32) had at least one grade 3-4 comorbidity, most often cardiovascular disorders 
(22%) or renal insufficiency (20%). 
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Table 2. Baseline characteristics of the patients (N=50)
Sex, n (%)
Male 25 (50)
Female 25 (50)
Age (years), n (%)
<75 17 (34)
75-80 20 (40)
>80 13 (26)
Diagnosis, n (%)
Acute Myeloid Leukaemia 17 (34)
Non Hodgkin Lymphoma 19 (38)
Myelodysplastic Syndrome 9 (18)
Multiple Myeloma 5 (10)
Weight (kg), mean (range) 71.7 (50 – 104)
Body Mass Index, mean (range) 26 (19.84 – 41.14)
Number of comorbidities, mean (range)
Grade 1 - 2 £ 3 (0 – 8)
Grade 3 - 4 £ 2 (1 – 5)
> 3 medications, n (%) 33 (66)
£  grade 1: mild problem, grade 2: problem of moderate severity requiring active therapy, grade 3: 
severe or constant disability, grade 4: extremely severe or urgent clinical problem
Complete CGA results were available for 45 subjects (90%); MMSE was not perfor-
med in 5 patients due to their poor health at the time of inclusion. Nutritional pro-
blems were frequent with 66% (N=33) being at risk of malnutrition (MNA-SF score 
8-11) and 16% (N=8) having malnutrition (MNA-SF score ≤ 7). The proportion of sub-
jects with an impaired score on each questionnaire is summarised in table 3. In total, 
88% (N=44) of patients had an abnormal CGA.
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Table 3. Questionnaires included in the comprehensive geriatric assessment (CGA) and proportion of 
subjects with an impaired questionnaire
Questionnaire Domain Score range Impaired score if
Number of 
patients with an 
impaired score 
(%)
ADL Autonomy 0-6 ≤ 5 12 (24)
IADL Autonomy 0-5 ♂0-8 ♀
≤ 4 ♂
≤ 7 ♀ 19 (38)
MMSE Cognitive functions 0-30 ≤ 23 2 (4.4)
GDS-4 Mood 0-4 ≥ 2 15 (30)
MNA SF Nutritional status 0-14 ≤ 11 41 (82)
CIRS-G Comorbidity 14 organ systems included
At least 1 
comorbidity 
grade 3/4
32 (64)
History of falls 
in the previous 
year
0-1 1 16 (32)
ADL: Activities of Daily Living; 
IADL: Instrumental Activities of Daily Living; 
MMSE: Mini Mental State Examination; 
GDS-4: 4 item Geriatric Depression Scale; 
MNA-SF: Mini Nutritional Assessment Short Form; 
CIRS-G: Cumulative Illness Rating Scale for Geriatrics
Performance of the G8 tool
Median score on the G8 screening tool was 12 (range 6.5-17) (fig.1); 76% (N=38) of 
patients scored ≤ 14 on the G8, indicating frailty (6). 
G8 SCREENING TOOL
 — 69
Figure 1. Results of the G8
In the analyses of the association between the G8 screening tool and the reference 
CGA, the ROC curve revealed a G8 score ≤ 14 as the optimal cut-off point, obtaining 
a sensitivity of 89% (95% CI 75-96) and a specificity of 100% (95% CI 54-100). The 
AUC ± SE was 0.949 ± 0.030 (fig.2). 
The inclusion of comorbidity in the CGA did not significantly change the performan-
ce of the G8 tool (0.943 ± 0.034; P = 0.895); nor did the G8 performance change 
when ADL or IADL were excluded from the CGA. 
Figure 2. ROC-curve analysis: performance of the G8 screening tool.
G8=14
AUC = 0.949
95% CI = 0.889 – 1.000
 G-8 cut off Sensitivity Specificity 
 13 77.3% 100% 
 13.5 81.8% 100% 
 14 88.6% 100% 
 14.5 88.6% 83.3% 
 15 95.5% 66.7% 
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DISCUSSION
The G8 has recently been developed as a screening tool to identify patients in need 
of further CGA and appropriate care. It has been validated in older patients with 
cancer in a large prospective multicentre study (6). Patients with various types of 
cancer were eligible for inclusion. Thirty percent of these patients were treated for 
Non-Hodgkin’s Lymphoma but no other haematological diagnoses were included. 
Since then, the G8 has been assessed in further studies, all of them including pre-
dominantly patients with solid tumours (14-16). 
To the best of our knowledge, our study is the first to validate the G8 as a screening 
tool in a population of older patients with only haematological malignancies. The 
G8 enables the appropriate selection of frail patients in need of a CGA. Additional 
information gathered by the CGA will inform individualised treatment plans for 
these frail patients. This is especially true in haematology, as more novel and pro-
mising approaches based on targeted therapies will become available in the next 
few years (3;17). 
At the cut-off score proposed in the literature (G8 ≤ 14), we obtained a sensitivity 
of 88.6% and a specificity of 100%, which is a similar sensitivity but a higher speci-
ficity than reported in previous studies validating the G8 screening tool in older 
cancer patients (18-22). 
Consistent with the findings of Bellera et al. (6), sensitivity and specificity estimates 
were comparable regardless of whether ADL, IADL, or both ADL and IADL were 
included in our CGA. We believe however that both ADL and IADL should be asses-
sed as they address different stages of dependence and can imply a difference in 
life expectancy. Impairments in ADL involve limited life expectancy and near-to-exhau-
sted functional reserve. For these patients, symptom palliation and quality-of-life 
preservation are essential (23), whereas patients with limitations only in IADL might 
benefit most from an individualised therapeutic approach.
The performance of the G8 tool did not change significantly when we included co-
morbidity in our CGA. In older cancer patients, comorbidity is an independent pre-
dictor of mortality and of survival (18-22). Comorbidity overlaps with, but is distinct 
from, frailty. Both comorbidity and frailty are independent risk factors for disabili-
ty. Therefore we would discourage the inclusion of comorbidity in a CGA. Patients 
with a normal score on the G8 screening tool will be excluded from further assess-
ment and incomplete or no information will be available about their comorbidity. 
Therefore, considering its predictive value, comorbidity should be assessed routi-
nely, preferably by means of a comorbidity scale, and independently of the G8 result.
Screening of older patients with cancer by means of the G8 is only a first step. Older 
patients scoring >14 should be considered “fit” and therefore receive the same tre-
atment as younger patients. However, older cancer patients with a score ≤ 14 should 
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not automatically be excluded from standard treatment. For these unfit patients, 
in a second step, a CGA might uncover those physical, psychological and/or functi-
onal impairments, limiting standard treatment options. Tailored interventions, ba-
sed on CGA results, might allow at least part of these unfit patients to benefit from 
standard treatment anyway (24).
With regard to prognosis in older patients with haematological malignancies, a few 
studies have demonstrated an impact of functionality on survival. However most 
studies on CGA and prognosis have focused either exclusively on solid tumours or 
on a general sample with a minority of haematological malignancies (1). So far no 
conclusions can be made regarding other CGA domains in terms of prognosis, nor 
in terms of quality of life.
Our study had several limitations. First, there might have been a referral bias. Only 
38% of our patients were dependent in IADL and only 4% had an abnormal MMSE 
score (< 24) at baseline. These are considerably lower percentages than those found 
in literature (25). As a tertiary centre, our hospital receives a significant number of 
patient referrals from other hospitals. Referring physicians may have considered 
older patients with physical, cognitive or emotional problems ill-suited candidates 
for aggressive therapy. Second, patients with haematological malignancies differ 
in several ways from patients with solid tumours. Due to a lack of studies in hae-
matology patients, we compared our results to those from studies of patients with 
solid tumours. Some differences in results can possibly be explained by differences 
between these patient populations. Finally, this was a cross-sectional study with 
the G8 and the CGA assessed on a single occasion.
In conclusion, our results show that the G8 tool can be used as a valid screening 
tool in older patients with aggressive haematological malignancies to identify frail 
patients who would benefit from a CGA. Comorbidity, however, should be assessed 
routinely, independently of the results of the G8.
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ABSTRACT
Objectives: Frailty is a geriatric syndrome characterized by decreased physiologi-
cal reserves and an age-related vulnerability to stressors with higher risk of adver-
se health outcomes. Comprehensive Geriatric Assessment (CGA) might detect frail-
ty but is time-consuming, implying the need for initial frailty screening. Most 
frailty screening tools do not include functional measures. Hand grip strength (HGS) 
is a reliable surrogate for overall muscle strength and predicts functional decline, 
morbidity and mortality. No studies are available in cancer patients on HGS as 
screening tool for frailty. We aimed to assess whether HGS can be used as a scree-
ning tool to predict an abnormal CGA and therefore frailty. 
Methods: Single centre cohort study in 59 patients aged 70 years or more with a 
haematological malignancy. HGS was measured using a vigorimeter. A patient was 
considered frail if any of the CGA-elements was impaired. 
Results: Mean HGS before start of therapy in women was 37.0 ± 14.3 kPa and in men 
66.1 ± 13.1 kPa. An abnormal CGA was present in 52 subjects (88%). HGS was asso-
ciated with concurrent abnormal CGA (p = 0.058 in women, p = 0.009 in men). AUC 
was 0.800 (SE = 0.130) in women and 0.847 (SE = 0.118) in men. Optimal HGS cut-off 
points for likelihood of abnormal CGA were ≤ 52 kPa in women and ≤ 80 kPa in men.
Discussion: In older patients with haematological malignancies, impairment in mus-
cle function is present at diagnosis. HGS seems a promising screening tool to iden-
tify patients with abnormal CGA.
INTRODUCTION
Frailty is a geriatric syndrome characterized by decreased physiological reserves 
and an age-related vulnerability to stressors resulting in a limited capacity to main-
tain homeostasis, thus increasing vulnerability to adverse health outcomes (1). One 
tool to detect frailty in older patients is the Comprehensive Geriatric Assessment 
(CGA). CGA is a multidimensional, interdisciplinary diagnostic process to evaluate 
an older person’s physical, psychological and functional capabilities and predict 
remaining life expectancy and functional age (2). CGA commonly includes an evalu-
ation of functionality, nutrition, emotional and cognitive function, polypharmacy, 
socio-economic issues and quality of life. In patients with cancer, the identification 
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of frailty might be relevant to detect potentially remediable medical problems with 
implications for prognosis, treatment and rehabilitation (3). However, one of the 
shortcomings of CGA is its time-consuming aspect. Therefore a two-step approach 
has been proposed with the use of a screening tool to detect possible frail patients 
that should subsequently undergo a CGA. Several screening tools exist but only five 
were specifically designed for older patients with cancer (4). One of them, the G8 
questionnaire, was recently validated in a subgroup of older patients with haema-
tological malignancies (5). 
Most screening tools currently used in patients with cancer are questionnaires. 
Only two studies applied the Fried frailty criteria for screening purposes (4). The 
Fried criteria comprise hand grip strength (HGS) as one of two performance-based 
measures for physical function. HGS is a valid and reliable measure of muscle 
strength and correlates well with total body muscle strength. In patients without 
cancer, low muscle strength is a clinical marker of poor mobility and an independent 
predictor of adverse health outcomes (6;7). In advanced cancer patients, lower HGS 
was associated with lower BMI, lower albumin, lower quality of life and poorer 
performance status (8). Consequently, HGS might be a suitable marker for frailty. 
So far, no studies are available in patients with cancer on the use of HGS as a single 
item screening tool for frailty.
The primary aim of this study was to evaluate HGS as a screening tool for frailty in 
older patients with recently diagnosed haematological malignancy before start of 
therapy. Secondary aims were to explore the association between HGS before start 
of therapy and 1) concurrent abnormal G8, 2) subsequent occurrence of adverse 
events during therapy, 3) subsequent 6-month mortality.
MATERIALS AND METHODS
Patients
This was a single centre cohort study. All patients aged 70 years or more with a 
new diagnosis of Acute Myeloid Leukaemia (AML), intermediate or high grade Mye-
lodysplastic Syndrome (MDS), Multiple Myeloma (MM) or high grade Non Hodgkin 
Lymphoma (NHL), who were referred to the haematology department of a tertiary 
hospital, were asked to participate in the current study. All participants provided 
written consent. The study was approved by the local Ethical Committee 
(B670201110554).
Hand grip strength 
HGS was measured before start of therapy, using a Martin vigorimeter. It consists 
of a rubber bulb connected by a tube to a manometer. The large bulb was selected 
for all subjects. Measures are expressed in kiloPascals (kP). Patients were sitting 
in a chair, shoulder adducted and neutrally rotated, elbow flexed at 90°, forearm in 
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neutral position, and wrist in slight extension (0° to 30°). Three consecutive HGS 
measurements of the dominant hand were taken with a brief pause between each 
measurement. The highest score was retained. 
Comprehensive Geriatric Assessment 
CGA was completed by a member of the geriatric team before start of therapy. 
Since no golden standard exists, our CGA included Activities of Daily Living (ADL) 
(9), Instrumental Activities of Daily Living (IADL) (10), 4-item Geriatric Depression Sca-
le (GDS-4) (11), Mini Mental State Examination (MMSE) (12), Mini Nutritional Assessment 
– Short Form (MNA-SF) (13), and any falls in the previous year. A patient was consi-
dered frail if at least one of the individual CGA-elements was impaired. 
Secondary outcomes
A G8 score was obtained by a member of the geriatric team before the start of 
therapy. Scores ≤ 14 were considered abnormal (5) .
Adverse events (AE) included any unplanned admission, treatment delay, dose re-
duction or disease progression. Only the first AE was taken into account. Data on 
mortality within the first six months were gathered from medical records.
Statistical analysis
Descriptive analyses were performed to describe patients’ characteristics. Nor-
mally distributed continuous variables were expressed as mean ± standard devia-
tion (SD). Countable variables were presented as absolute number (N) and percen-
tage (%) of the study population. Independent samples T-tests were used to detect 
differences in HGS between groups. Age-adjusted logistic regression analyses 
further explored the association between HGS and abnormal CGA, abnormal G8 
score, occurrence of adverse events, and 6-month mortality.
The performance of HGS as screening tool for concurrent abnormal CGA was also 
evaluated using Receiver Operating Curve (ROC) analyses and the area under the 
ROC curve (AUC) with standard error (SE). Sensitivity and specificity were calcula-
ted at the cut-off point with the highest value of the Youden’s index. 
All analyses were performed using SPSS software, version 21.0.0.1. Statistical sig-
nificance was indicated by a P value < 0.05; all P values were two-tailed. 
RESULTS
Between June 2011 and January 2013, 71 patients were included in the study. Of 
these, 59 had complete data on HGS and CGA before start of therapy. Mean age was 
77.3 ± 4.8 years. Mean HGS before start of therapy in women was 37.0 ± 14.3 kPa, 
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in men 66.1 ± 13.1 kPa. Further baseline characteristics are summarized in table 1. 
Adverse events were registered for 35 patients (59%). Within the first six months, 
17 patients died (29%). 
Differences in HGS between subjects with normal / abnormal CGA, normal / ab-
normal G8, none / at least one adverse event, 6-months survival / mortality accor-
ding to gender are described in table 2. Furthermore, results from logistic regres-
sion analyses adjusted for age are presented in table 2.
Figure 1 shows the ROC curves of HGS as screening tool for concurrent abnormal 
CGA in women and men. Criterion for HGS associated with the Youden’s index in 
women is ≤ 52 kPa (88% sensitivity and 67% specificity) and in men it is ≤ 80 kPa 
(93% sensitivity and 75% specificity).
Table 1. Characteristics of the study population before start of therapy (N = 59).
Characteristic N (%)
Gender, female 28 (48)
Age, 80 years or more 21 (36)
Diagnosis
Acute Myeloid Leukaemia
Non Hodgkin Lymphoma
Myelodysplastic Syndrome
Multiple Myeloma
17 (27.9)
24 (39.3)
11 (18.0)
9 (14.8)
IADL dependency 22 (37)
MMSE < 24 4 (7)
CGA, ≥ 1 impairment 52 (88)
CGA, ≥ 2 impairments 34 (58)
G8 ≤ 14 46 (78)
IADL = instrumental activities of daily living, MMSE = mini-mental state examination, 
CGA = comprehensive geriatric assessment
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Table 2. Association between hand grip strength and abnormal comprehensive geriatric assessment, 
abnormal G8, occurrence of adverse event(s), and survival status according to gender (N = 59).
HGS (kPa)
Normal CGA
mean ± SD
Abnormal CGA
mean ± SD
P a OR b 95% CI b P b
Women 51.7 ± 13.1 35.2 ± 13.6 0.058 0.89 0.77 - 1.02 0.099
Men 81.5 ± 12.8 63.9 ± 11.7 0.009 0.85 0.72 - 1.00 0.044
 HGS (kPa)
Normal G8
mean ± SD
Abnormal G8
mean ± SD
P a OR b 95% CI b P b
Women 48.7 ± 14.4 33.8 ± 12.8 0.021 0.91 0.82 - 1.00 0.051
Men 72.4 ± 14.8 64.3 ± 12.3 0.152 0.96 0.89 - 1.03 0.269
 HGS (kPa)
0 adverse 
event
mean ± SD
 ≥ 1 adverse 
event
mean ± SD
P a OR b 95% CI b P b
Women 42.3 ± 9.1 34.9 ± 15.6 0.136 0.96 0.90 - 1.02 0.206
Men 63.6 ± 11.2 68.8 ± 14.8 0.28 1.04 0.98 - 1.11 0.173
 HGS (kPa)
Alive
mean ± SD
Death
mean ± SD
P a OR b 95% CI b P b
Women 38.6 ± 14.9 29.6 ± 8.4 0.207 0.95 0.88 - 1.03 0.204
Men 67.0 ± 12.7 64.8 ± 14.2 0.65 1.00 0.94 - 1.06 0.961
HGS = hand grip strength, SD = standard deviation, CGA = comprehensive geriatric assessment, OR = odds 
ratio, CI = confidence interval
a Independent-samples T test
b Age-adjusted logistic regression analysis
DISCUSSION
The primary aim of our study was to evaluate HGS as a screening tool for frailty in 
older patients with haematological malignancies. HGS was significantly higher in 
patients with a normal CGA compared to those with an abnormal CGA. Optimal 
cut-off points for likelihood of an abnormal CGA were ≤ 52 kPa in women and ≤ 80 
kPa in men, respectively. Furthermore, HGS was significantly associated with ab-
normal G8 in women, but not in men. 
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Figure 1. Receiving operating curves of hand grip strength as screening tool for concurrent abnormal 
comprehensive geriatric assessment according to gender.
HGS = hand grip strength, AUC = area under the curve, SE = standard error
HGS in patients with recently diagnosed haematological malignancy
Desrosiers et al. developed normative data for the Martin vigorimeter, according 
to age and gender (14). Compared to these normative data, mean GS in our study 
population was less than expected for both men and women, in each age category. 
Christensen identified 194 studies reporting measures of muscle function, including 
muscle strength, in adult cancer patients. Studies reporting on muscle strength, in 
their entirety, indicate that cancer patients have significant impairments in muscle 
strength regardless of disease stage (15). Except for the study of Burney et al., inclu-
ding ten patients with leukaemia or lymphoma, all included patients were diagno-
sed with a solid tumour (16). Our findings demonstrate that, also in patients with a 
haematological malignancy, a loss of upper extremity strength is present, even 
before the start of treatment. As in patients with solid tumours, the aetiology of 
haematological cancer-related muscle dysfunction might comprise comorbidities, 
malnutrition and/or weight loss with the resultant loss of muscle mass, physical 
inactivity and systemic inflammation due to pro-inflammatory cytokines (15).
HGS and subsequent health-related outcomes
We could not detect any significant associations between HGS and subsequent 
adverse events or 6-month mortality. Epidemiological studies in the general popu-
lation found HGS to be predictive for increased risk of functional limitations and 
disability, and all-cause mortality (7;17-19). In patients, HGS was strongly predictive of 
postoperative complications, length of stay, loss of functional status and short term 
survival (19). Studies on the predictive value of HGS in cancer patients are limited. 
Two studies comprising patients with various cancers found HGS to be significant-
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ly associated with survival (8;20). Another three studies found lower HGS to be pre-
dictive of postoperative complications (21-23) and mortality within 6 months after 
the operation (22). In patients with haematological malignancies, only one study 
could be identified. Similar to our results, no relation could be found between physi-
cal function, including HGS, and short-term mortality (60 days) or ICU admission 
(24). This absence of correlation in oncohaematological patients might be related 
with some of the features of haematological malignancies: the existence of treat-
ments offering good chances of cure or long-term remission, even in advanced 
stages, and often a rapid response to chemotherapy with subsequent marked im-
provement in functionality (25).
Our study had several limitations. First, it was a single centre study with small sam-
ple size. Some of the non-significant associations we found might be due to lack of 
power. Second, there might have been a referral bias. Only 37% of our patients were 
dependent in IADL and only 7% had an abnormal MMSE score (< 24) at baseline. 
These are considerably lower percentages than those found in the literature (26). As 
a tertiary centre, our hospital receives a significant number of patient referrals 
from other hospitals. Referring physicians may have considered older patients with 
physical, cognitive or emotional problems ill-suited candidates for aggressive the-
rapy. Third, in several centres a Jamar dynamometer is used to measure HGS instead 
of a Martin vigorimeter. Although highly correlated, these results are not interchan-
geable, and therefore additional research is needed as to which cut points apply to 
the Jamar dynamometer.
To the best of our knowledge, this is the first study on the use of HGS as screening 
tool for frailty in patients with haematological malignancies. HGS is a simple per-
formance test, feasible in a busy clinical practice, and potentially a quick and valid 
alternative for screening questionnaires. HGS and CGA data were collected from 
patients simultaneously which strengthens the consistency of our data. So far, no 
cross-sectional data are available comparing HGS with the results of a subsequent 
CGA. The use of a CGA, currently the gold standard to confirm frailty in older adults, 
as the reference frame can be considered an additional strength of our study.
In conclusion, this study suggests that HGS might be a promising screening tool in 
older patients with aggressive haematological malignancies to identify possibly 
frail patients who would present with abnormal CGA. This finding however requires 
validation in a larger multicentre prospective study. 
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1.  MAIN FINDINGS
The aim of this doctoral thesis was to explore the added value of a comprehensive ge-
riatric assessment (CGA) in the detection of frailty and/or additional geriatric syndromes 
in older patients with haematological malignancies. Furthermore, we examined whether 
the results of screening and CGA were predictive for adverse events or mortality.
In Chapter 1 we provide a general overview of the literature on haematological malig-
nancies in older patients. In addition to disease characteristics and treatment principles, 
we focus on the features of frailty and CGA. As the process of frailty can be changed 
or reversed, one of the main challenges in geriatrics is the detection and in-depth eva-
luation of frail individuals, by means of a CGA, to determine who might benefit by me-
dical and rehabilitation efforts. The lack of studies on the use of CGA, specifically in 
patients with haematological malignancies, was the starting point of this thesis.
In Chapter 2 (i.e. papers 1 and 2) we focus on the geriatric problems we most fre-
quently encountered when administering a CGA, and their importance for this spe-
cific group of patients.
The administration of a CGA is both time and staff-consuming. Therefore, a two-
step approach is proposed with the use of a screening tool as the first step to iden-
tify those patients that subsequently would benefit most from a CGA.
In Chapter 3 we therefore test the performance of the G8 questionnaire as a scree-
ning tool for frailty in this group of patients.
In Chapter 4 we aim to assess whether functional measures like hand grip strength 
can be used as a screening tool, instead of questionnaires.
In Chapter 5 the major findings of each paper are recapitulated in the boxes. In the 
discussion we focus on implications and recommendations for current clinical prac-
tice while future perspectives for practice and research will complete this chapter.
1.1 Chapter 2
Analysis of the first results showed that 88% of patients had an impaired score for 
at least 1 CGA item. Further analysis of all results revealed some “red flags”, i.e. a 
remarkably high number of patients with potential nutritional problems and a high 
rate of polypharmacy, indicating the necessity of further in-depth evaluation.
1.1.1 Chapter 2.1
The first paper addressed the baseline nutritional status of a group of older patients 
with haematological malignancies. In this observational monocentric study, 70 pa-
tients were screened for malnutrition by means of the MNA-SF, before the start of 
chemotherapy.
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Using the MNA-SF, 81% of patients screened positive, with 61% conside-
red at risk for malnutrition and 20% malnourished. On the second eva-
luation, two months later, 1 of the patients with a normal score had died 
while 9 more patients scored positive on MNA-SF, resulting in 95.7% 
(CI95 = 83-99%) of patients with (risk for) malnutrition.
However, only 41% of our patients had a BMI < 25. In routine clinical 
practice a low BMI is still often used as an indicator of malnutrition. Our 
study shows that using BMI, as an indicator for chronic malnutrition, 
might result in a delay of adequate nutritional support. 
Most often patients scored positive on recent weight loss and declined 
food intake, both common side-effects of chemotherapy. Thus, during 
treatment, the percentage of patients with a positive screen can only 
rise. Given the high prevalence of malnourished patients or patients at 
risk, one can question whether screening for malnutrition, at least by 
means of the MNA-SF, is meaningful in patients with haematological 
malignancies, or whether nutritional assessment should be considered 
the first step approach. This assessment. incorporating also anthropo-
metric measurements, comorbidity, and current and foreseen medica-
tion should be dedicated to a skilled dietician, preferably with an exper-
tise in oncology.
This is, to our knowledge, the first report on the baseline nutritional sta-
tus in a group of older patients with a diagnosis of an aggressive hae-
matological malignancy.
The high number of patients with possible nutritional problems was mainly due to 
a high percentage of patients at risk and strikingly higher (61% vs. 37%) than what 
was found in the only available study in patients with (malignant and non-malig-
nant) haematological disorders (1). Moreover, about half of the patients from that 
study were free of nutritional problems in contrast to 19% in our study population. 
In comparison, in a review published in 2014, in a wide variety of patients with va-
rious types of cancer, the prevalence of nutritional problems, based on the MNA, 
ranged from 42% to 83% (2). Consequently, our results are in line with those in pa-
tients with solid tumours. 
Since the MNA has not been validated to detect malnutrition in patients with can-
cer, one could argue that some items of the MNA scale could have been altered by 
the (haematological) disease, more than by malnutrition. Despite this lack of vali-
dation, at least 3 studies recently found a significant negative relationship between 
nutritional status assessed by MNA, and treatment complications or mortality (3-5). 
The Chemotherapy Risk Assessment Score for High-age patients (CRASH) score, 
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 developed by Extermann et al., allows stratifying patients into 4 risk categories for 
severe chemotherapy toxicity. The instrument is valid across a wide range of chemo-
therapies. Low MNA, amongst other patient and cancer characteristics, was corre-
lated with a higher risk of grade 3/4 non-haematological toxicity (4). In a group of 202 
patients with various cancers and an indication for chemotherapy, inferior MNA 
scores increased the probability of not completing chemotherapy, and also, showed 
an increased mortality risk after the start of chemotherapy (3). There is only one stu-
dy in patients with advanced lung cancer comparing MNA with weight loss (5). The 
incidence of malnourished patients or patients at risk was higher with the MNA. MNA 
correlated with the number of metastatic sites and also with 9 of 14 laboratory va-
lues indicating adverse prognosis, malnutrition and inflammation-cachexia. Moreover, 
it was superior to weight loss history in the prediction of response to first-line tre-
atment, time to progression and overall survival. Furthermore MNA refined short-
term survival estimates, dividing patients in 3 categories (adequately nourished, risk 
of malnutrition, malnourished) with distinct median and 1 year survival.
Although it remains unclear whether a lower MNA score is an expression of (more 
progressive) disease, a true proof of malnutrition, or a combination of both, it is clear-
ly shown that a low MNA score should raise concern about a patient. Moreover, if a 
low MNA score truly reveals (a risk of) malnutrition, MNA stratifies a group of patients 
with intermediate risk in which early anticachectic strategies and/or nutritional in-
terventions might be more effective due to the timely demonstration of nutritional 
deterioration (5). For the moment however, the number of studies on nutritional in-
terventions is small and the data are heterogeneous, requiring further research (6). 
Implications for clinical practice: 
Many older patients with a haematological malignancy facing aggressive therapy 
are malnourished or at risk for malnutrition, according to the MNA-SF. Therefore, 
as to the aspect of nutrition, our findings support baseline nutritional assessment 
by a dietician with dietary advice and follow-up during treatment to become an 
integrated part of the treatment plan for every individual patient. As to the aspect 
of prognosis however, it might be worthwhile to keep using the MNA, as it can yield 
additional information on the risk of treatment complications and/or median and 
overall survival.
1.1.2 Chapter 2.2
In the second paper of this chapter we examined the loss of autonomy in medica-
tion management after start of therapy and elaborated on predetermining factors. 
In this longitudinal monocentric cohort study 62 patients underwent a geriatric 
evaluation before and two months after start of therapy. Medication was registe-
red both times. 
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Due to the initiation of chemotherapy and supportive drugs, patients 
with a haematological malignancy are confronted with extensive chan-
ges in medicinal treatment. In a single center cohort study we recorded 
alterations in medication regimen and concurrent changes in autonomy 
in medication management, based on IADL. 
Polypharmacy increased from 48.3% of patients at baseline to 98.3% 
after start of therapy. At baseline, 79% of patients took their long-term 
medication independently. Being independent for medication manage-
ment is significantly associated with the absence of polypharmacy. More 
than half of the formerly independent patients needed assistance for 
their medication after start of therapy. 
IADL provides no information with regard to the cause of the incapacity. 
After careful consideration of all CGA data, drug regimen complexity 
seemed the most plausible explanation: apart from an increase in the 
number of medications, multiple daily doses, varying doses, and medi-
cation splitting further contributed to regimen complexity. 
So far, little attention is paid to (unintentional) non-adherence due to 
functional problems or changes, despite the fact that older patients ex-
perience a gradual decline in their cognitive and functional abilities re-
quired for medication management. 
The merit of this study lies in the fact that our findings might make health 
care professionals more aware of the huge impact of polypharmacy, 
frequent drug regimen changes, and regimen complexity during cancer 
treatment, especially in older patients. Moreover, the finding of this pa-
per might draw attention of health care professionals to some unmet 
needs in current care pathways.
Besides problems with medication management related to polypharmacy, this 
chapter highlights another aspect in the care of older people receiving intensive 
treatment. This study clearly shows that patients, during chemotherapy, might 
develop new geriatric syndromes. This finding stresses the need for some kind of 
repetitive CGA evaluation. A CGA is both a diagnostic and therapeutic tool and 
should per definition include long-term follow-up. However, in an era where rese-
arch mainly focuses on how to minimize the initial “comprehensive” geriatric as-
sessment, recommendations on how and when to re-evaluate older patients with 
cancer still need to be formulated.
During the course of our study, patients had 1 or 2 follow-up visits, depending on 
treatment modalities. Except for patients with undeniably poor overall condition, 
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a second and eventually a third CGA was performed. However, due to the low num-
ber of surviving patients, we could not make any firm conclusions on the evolution 
of CGA items, except for autonomy in medication management (see above). Regar-
ding cognition, we did not record apparent changes in MMSE overtime, keeping in 
mind however the low number of survivors and a rather short follow-up period to 
detect changes in mental functioning. Other items like ADL or quality of life did 
worsen for some and improved for others, without apparent correlation. 
Apart from our study, three more articles could be found reporting on the results 
of consecutive CGA evaluations. In one study in community-dwelling older patients 
there was a continued yield of problems identified and recommendations made 
when CGA was repeated annually for 3 years (7). There is one study in patients with 
breast cancer with a median age of 79 years. Each patient underwent a CGA at ba-
seline and every 3 months, structured follow-up from the nurse practitioner, die-
titian, social worker and/or pharmacist according to risk assignment, and specific 
interventions if necessary. CGA initially detected 6 problems and on average 3 new 
problems during a follow-up period of 6 months. A significant number of these 
problems interfered with cancer treatment. The study concerned a patient group 
with a rather simple oncological treatment. The authors therefore concluded that 
one can expect an even greater benefit from a comprehensive follow-up in patients 
with more complex oncological treatment (8). In the third study, in head and neck 
cancer patients undergoing curative radio(chemo)therapy, patients were assessed 
before and 4 weeks after start of treatment (9). During treatment, the incidence of 
vulnerability increased in most domains included within the CGA, with especially 
deterioration of nutritional, functional and emotional status. 
In 2014, a study protocol was published for a multicentre randomized controlled 
trial in head and neck cancer patients (10). Apart from a CGA at baseline, a standar-
dized geriatric follow-up is planned for 1 to 6 months. This follow-up each time in-
cludes a brief assessment of nutrition, mood, pain, functional status, five comorbi-
dities, self-perceived health status, and medication use as well as implementation 
of interventions. The primary aim of the EGeSOR1 trial hereby is to demonstrate 
that multidimensional geriatric interventions based on an initial CGA might impro-
ve outcome. In addition, it might give direction to how (which domains) and when 
(visit frequency) older patients should be re-evaluated. Estimated study completi-
on date is September 2018. 
Implications for clinical practice:
In an era of hospital accreditation and the constant pressure to establish quality indi-
cators regarding appropriate medication use, our findings depict a clearly defined tar-
get group for suitable intervention. Emphasis should be placed on the development of 
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a multidisciplinary “self-administration of medications (SAM) program”, adapted for 
older ambulatory patients and based on information, education and medication pre-
paration under supervision. Current literature on SAM has focused almost exclusively 
on inpatients. No suggestions could be found on SAM in an outpatient clinic. Based on 
what is known in the literature, assessment of medication management should be 
combined with (pharmacist-led) medication reconciliation. Moreover, it was shown 
that pharmacists who work in the context of a geriatric multidisciplinary team are more 
successful in reducing iatrogenic illness in older adults due to a global assessment: du-
ring medication review not only clinical but also functional parameters could be taken 
into account (11). Thus, in an ideal world, patients should have a CGA, followed by medi-
cation reconciliation, keeping in mind the results of the geriatric assessment. After 
discussion with the treating physician and the creation of a medication plan, patients 
should be informed. Finally, medication management should be assessed, using a va-
lidated instrument preferably based on the use of own medication.
Furthermore, pending the results of larger, multicentre trials, local geriatric and 
oncological teams should seek for the best possible way to incorporate the concept 
of CGA as a whole (assessment, recommendations and interventions), with some 
form of long term follow-up included.
1.2 Chapter 3
One of the main concerns of a geriatric assessment is the time and the staff needed 
to provide a comprehensive picture of a patient, including a report on the deficits 
that are detected and suggestions to improve overall functionality/health. Moreover, 
there is a group of obviously fit older patients for which a CGA might not be neces-
sary. Therefore, the use of a two-step approach has been promoted with initial 
screening and subsequent CGA if indicated. A wide variety of screening tools are 
used in oncology, including G8. In the third paper we focused on the performance 
of the G8 screening tool in patients with a haematological malignancy. Fifty patients 
were included in this cross-sectional study. G8, CGA (consisting of six questionnai-
res) and CIRS-G were completed for each patient. CGA was considered abnormal 
when at least one questionnaire showed an impaired score.
We could validate the G8, at the cut-off score of G8 ≤ 14, in a population 
of older patients with only haematological malignancies. We thereby 
obtained a sensitivity of 88.6% and a specificity of 100%. 
Sensitivity and specificity estimates were comparable regardless of 
whether ADL, IADL, or both ADL and IADL were included in our CGA. 
However, as ADL and IADL address different stages of dependence, with 
an inherent difference in life expectancy, both should be assessed.
The performance of the G8 did not change significantly when we inclu-
ded comorbidity in our CGA. In older cancer patients, comorbidity is an 
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independent predictor of mortality. It overlaps with, but is distinct from, 
frailty. Therefore comorbidity should be assessed routinely, independent 
of the G8 result.
This study was, to the best of our knowledge, the first to validate the G8 
as a screening tool in a population of older patients with only haemato-
logical malignancies.
Recently, 2 reviews highlighted most commonly used screening tools and their per-
formance (12;13). Through studies, sensitivity was high (>80% in six of eight studies). 
Specificity on the other hand was rather moderate. In this review our analyses were 
not yet included (not published yet). With a comparable sensitivity and a higher 
specificity, our results support the use of G8 as a screening tool, also in patients 
with haematological malignancies.
G8 is to a great extent derived from the MNA. Therefore, in the process of valida-
tion, comparing G8 to a CGA comprising the MNA might raise the question whether 
we selected frail patients or just patients at risk for malnutrition.
No studies are yet published in which G8 is compared to a reference CGA containing 
another nutritional risk score than the MNA (14-20). However, in the development of 
the G8, one has made sure that several domains were covered that are usually as-
sessed by a geriatrician during the course of a CGA, with only 3 items directly rela-
ted to nutrition (21). Furthermore, indirectly, we can presume from our results that 
G8 does indeed select a frail group of patients. First, when we, in our population, 
excluded the MNA from the CGA, 64% of patients (compared to 88%) remained frail, 
which is most likely an underestimation as no nutritional assessment is than incor-
porated in the CGA. Second, as we discussed already as a result of the first paper, 
a low MNA score, irrespective of the underlying mechanism, should raise concerns 
about a patient. The same therefore can be assumed for a lower G8 score. Third, 
the correlation we found between G8 score and hand grip strength (HGS), if con-
firmed in larger studies, might prove an additional argument. This argumentation 
is further supported by recent literature. In one study, older patients with a normal 
G8 had a low risk for functional decline in ADL and a less pronounced decline in 
IADL. Moreover, several studies have shown that abnormal G8 is associated with 
grade 3/4 chemotherapy toxicity and overall survival, although not in haematolo-
gical malignancies (17;22;23). 
Implications for clinical practice:
Based on our results, the G8 tool can from now on be used as a valid screening tool 
for frailty, also in older patients with haematological malignancies. In addition, and 
thus independently from the results of the G8, comorbidity should be assessed in 
every patient, also in the apparently fit.
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1.3 Chapter 4 
In this chapter we assessed the possibilities of HGS as a screening tool for frailty 
and its association with G8 and outcome respectively. In this single centre cohort 
study, HGS was measured in 59 patients, using a vigorimeter. As in Chapter 3, a 
patient was considered frail if any of the CGA-components was impaired. 
Mean HGS before start of therapy was 37.0 ± 14.3 kPa in women, 66.1 ± 
13.1 kPa in men. Compared to normative data, mean HGS in our popula-
tion was below expected for both men and women, in each age catego-
ry. Furthermore, HGS was significantly associated with abnormal G8 
and was significantly higher in patients with a normal CGA compared to 
those with an abnormal CGA. 
Optimal cut-off points for likelihood of an abnormal CGA were ≤ 52 kPa 
in women (88% sensitivity and 67% specificity) and ≤ 80 kPa in men (93% 
sensitivity and 75% specificity), respectively. 
Adverse events were registered for 35 patients (59%). Within the first 
six months, 17 patients died (29%). We could not detect any significant 
associations between HGS and subsequent adverse events or 6-month 
mortality.
Our results suggest that HGS might identify possibly frail patients who 
would benefit from a CGA and thus, potentially, a quick and valid alter-
native for screening questionnaires.  Our findings however require va-
lidation in a larger multicentre prospective study. 
This study, to the best of our knowledge, proved to be the first attempt 
on the use of HGS as a single item screening tool for frailty in patients 
with haematological malignancies. 
Keeping in mind the results presented in Chapters 3 and 4, logical question emerges 
on which one of two options, G8 or HGS, should be preferred as a screening tool. 
The answer however is far less obvious.
G8 has been developed specifically as a screening tool for frailty in older patients 
with cancer. G8 has proven, in different populations and different tumour types, 
to detect 87% of frail patients overall. However, as for all screening tools, specifici-
ty and negative predictive value are considered poor (13).
Like G8, most screening tools used in the decision process whether or not to refer 
an older patient (any older patient) for further geriatric evaluation, are question-
naire- rather than performance-based. Questionnaires, if self-administered, are 
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cost and timesaving. However, and especially important in older people, they as-
sume sufficient literacy, visual acuity and (residual) cognitive skills or the presence 
of a caregiver. Moreover, there is the risk of misinterpretation of what is being as-
ked, and of a patient overestimating his (physical) capabilities. Also, the patients’ 
desire to give socially acceptable answers should be taken into account. Moreover, 
questionnaires might lack sensitivity for detecting small changes. 
A performance-based assessment requires to perform a task on-site rather than 
to select an answer from a list and might therefore be a more valid indicator of pa-
tients’ abilities. Also, sensitivity to clinical change is often better. More specific in 
the light of this thesis, measuring HGS requires minimal equipment and time, places 
low demand on performing staff and is well-tolerated, even by wheelchair-and 
bed-bound patients (24).
Research on HGS and its association with frailty has developed exponentially after 
the introduction of the frailty phenotype, introduced by Fried et al. According to 
the Fried criteria patients were considered frail in the presence of 3 or more of the 
following characteristics: unintentional weight loss of ≥10 pounds or ≥5% of BW in 
the previous year, HGS in the lowest quintile, self-reported exhaustion, slowness 
in walking speed, and low physical activity level. HGS, as a single item or as part of 
the Fried criteria, has been associated with mortality, disease-specific morbidity 
and disability in various populations, ranging from healthy seniors living in the 
community to patients with chronic diseases including cancer, and geriatric inpa-
tients (24-28). For most of these studies, the prognostic value of HGS as a frailty mar-
ker was determined in relation to firm clinical endpoints rather than the results of 
a comprehensive geriatric assessment. 
In patients with cancer only 2 studies could be identified using the Fried criteria 
and none using HGS as a frailty screening tool in reference to a CGA (12;29;30). To the 
best of our knowledge, our study proved to be a first attempt to determine limits 
of strength below which every patient should be assessed by means of a CGA for 
the presence or absence of frailty. These findings however require validation in a 
larger multicenter prospective study. In accordance with the primary aim of a scree-
ning tool, i.e. to identify all patients at risk for functional decline, we obtained a high 
sensitivity. Specificity on the other hand is, as with most screening tools, rather 
low with at least 1 out of 4 patients unnecessarily undergoing a CGA.
 
Based on the current scarce literature, direct comparison between both G8 and 
HGS as screening tools for frailty is not possible. Our own analyses found no signi-
ficant difference in AUC between G8 and HGS, potentially due to a lack of power. 
We did find a correlation between G8 and HGS for women. Although median HGS 
was higher also in the group of patients with G8 > 14, no significant correlation could 
be found for men. Partly due to the limited number of patients included in the sam-
ple, we are neither able to say whether both tools identify the same patients as 
being frail, nor to mention whether one tool is more prognostic than the other.
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A third option, in addition to the use of G8 and HGS respectively, might be the com-
bined use of G8 and HGS, thereby encompassing subjective as well as objective 
measures, i.e. questions as well as performance. Based on our limited data, combi-
ning G8 and HGS did not provide an added value. In the literature discussion is still 
going on as to whether cognition and mood should be considered additional dimen-
sions of frailty or just comorbid conditions, catalyzing the transition from frailty to 
overt disability (31). 
To a lesser extent, there is also the debate on the social dimension of frailty. A re-
cent article favoured a broader approach towards frailty. Ávila-Funes and collea-
gues determined that adding cognitive impairment to the Fried criteria improved 
its’ predictive value (32). De Vries et al. listed 8 frailty (risk) factors, i.e. nutritional 
status, physical activity, mobility, energy, strength, cognition, mood and social sup-
port, considered to be of great importance to the concept of frailty (33). HGS clearly 
comprises just 1 frailty factor and thus 1 frailty domain. G8 on the other hand covers 
nutritional status, mobility, cognition and mood, i.e. 4 frailty factors and 2 frailty 
domains. Theoretically, combining both covers 1 additional frailty factor and might 
therefore better reflect the interaction between health domains and the multidi-
mensionality of the frailty concept, and thus better fit with the holistic approach 
typical for a geriatrician. 
Finally, but equally important, one should take into account that the selection of a 
screening tool might vary, depending on the situation and the subpopulation of frail 
older people under study. This might be especially true for intervention studies. 
Implications for clinical practice:
HGS is a simple performance test, feasible in a busy clinical practice, and potentially a 
quick and valid alternative for screening questionnaires. Our results regarding HGS 
however are preliminary and require validation in a larger multicentre prospective 
study. Therefore, implications for clinical practice are limited for the moment. Haema-
tology departments in possession of a Martin vigorimeter might consider determining 
HGS in addition to their usual work out. This will allow to gain insight in baseline HGS 
and its association with CGA, its evolution during and after treatment and its correla-
tion with clinical outcomes, by analogy with current trends in cardiology (24;31). 
Through the writing of this thesis, data on quality of life were not discussed. Nevert-
heless it was stipulated in the study protocol that for all patients quality of life should 
be assessed using the FACT-G. However, after six months, full data were available only 
for 29 patients. Main reasons for not completing the questionnaire were 1) the exten-
siveness of the questionnaire and 2) the confronting nature of some of the questions. 
Over 6 months, total FACT-G score improved from 73 to 80 (p = 0.007). Functional well-
being improved from 13 to 16 (p = 0.019), as did physical well-being (from 23 to 26; p = 
0.004). Quality of life improved more in patients with normal MNA-SF score at base-
line than in malnourished patients or patients at risk. Social well-being and emotional 
well-being appeared to remain stable over time. However, these findings are prelimi-
nary and must be interpreted with caution. Further research is clearly needed.
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2. LIMITATIONS OF THE THESIS
First, one main limitation of this thesis is the fact that the presented data are main-
ly explorative. In preparation of this study, on 19 January 2011, a rough search 
through PubMed was performed on existing literature concerning the use of a CGA 
in patients with a haematological malignancy. Combining the MESH terms “geriatric 
assessment” and “Hematologic Neoplasms”, “Lymphoma, Non-Hodgkin”, “Myelo-
dysplastic Syndromes”, Multiple Myeloma”, and “Leukemia, Myeloid, Acute” respec-
tively, resulted in a total of 20 hits. These included 7 reviews, 1 author reply and 2 
posters without article publication. In comparison, the combination of “geriatric 
assessment” and “breast neoplasms” identified 121 articles. These figures just illus-
trate that, the moment our research started, no directive information was available 
on the target population, the format of the CGA, the feasibility of performing a CGA, 
the integration of CGA results in daily practice, or its correlation with clinical out-
comes. Evidence still had to be built. This thesis therefore should be considered a 
first exploration of the terrain. For the sake of completeness, we repeated the se-
arch almost 5 years later, on 1 December 2015. This resulted in 27 additional publi-
cations (compared to almost 50 on breast neoplasms) of which at least 12 were 
reviews. Current research hereby seems to focus on AML and NHL. Overall, we can 
argue that interest in this group is growing although there is still a big gap. Hereby 
we have to bear in mind that, although incidence of haematological malignancies 
is rising with age, the absolute number of new cases per year is still limited. Inclu-
sion of a sufficient number of patients therefore can take several years and there-
fore also the publication of new results. Moreover, in recent years, some major 
studies were published on a mixed population of patients with solid tumours as 
well as patients with haematological malignancies. These studies also provide – 
perhaps more global, but certainly relevant and renewing - insights in the approach 
of an older population with haematological malignancies.
Second, there might have been a referral bias. Only a minority of our patients was 
found to have functional or cognitive impairments. This is considerably less than 
what can be found in the literature (34). As a tertiary centre, a significant number of 
patients are referred from other hospitals. Referring physicians may have consi-
dered older patients with physical, cognitive or emotional problems no longer can-
didates for aggressive therapy. Moreover, some patients and/or their caregivers 
were reluctant to participate in a clinical study. 
Third, the sample size was relatively small due to the monocentric nature of the 
study, a possible referral bias, and the initial reluctance to participate. No sample 
size calculations were available at onset of the study. By referring to previous re-
search, we were able to prove sufficient power for the study on the validation of 
the G8. For the other studies, no reference articles were available as such. For some 
outcome measures (mortality, adverse events, quality of life) post hoc power ana-
lysis could have been worthwhile. Overall, 71 patients were included consecutively, 
while 14 patients refused to participate. All analyses were performed in the same 
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(sub)group of patients. No corrections were made for possible alpha-inflation. Of 
the 71 patients included, 5 patients dropped out and 2 patients were lost to fol-
low-up. In addition, almost one third of patients died within the first six months. 
Therefore, no firm conclusions could be drawn on outcome or other clinically me-
aningful endpoints like adverse events, the evolution of HGS or quality of life.
Fourth, since no golden CGA exists, we retained a set of six validated questionnaires, 
which are routinely used and often considered as components of a CGA. Choices 
have also been influenced by personal experience, feasibility, extensiveness, and 
the potential to compare with current literature. No single questionnaire results in 
a perfect assessment but, in the light of this thesis, for some instruments a critical 
appraisal is desirable. Lawton IADL is a commonly used index to measure functional 
status. Limitations of Lawton IADL can include the self-report or informant report 
method of administration rather than performance of a functional task, which ma-
kes it relatively quick and easy to administer, but which might lead either to over- or 
underestimation. Lawton IADL relies on a single item to assess functional ability 
within complex domains such as medication management. In addition, it may not be 
sensitive to small incremental changes in function. It also provides no information 
as to the cause of the incapacity (35). The MMSE is the most commonly administered 
cognitive screening test. Although sensitive for overt dementia, its utility decreases 
when patients with mild cognitive decline or psychiatric conditions are assessed. 
The MMSE may lack sensitivity to early signs of dementia. Moreover, repetitive tes-
ting in short time intervals with the same instrument may produce practice effects. 
For high-level IADLs such as medication management, MMSE has demonstrated 
inconsistent relationship with functional performance and lacks sensitivity in dis-
criminating competent from incompetent individuals (35). We therefore cannot ex-
clude that, despite normal MMSE score, for some patients MCI might have been the 
cause for a loss of autonomy in medication management. Finally, no clear definition 
exists as to what constitutes an abnormal CGA in relation to frailty. In accordance 
with previous research, we therefore considered the presence of at least one ques-
tionnaire with an impaired score as an abnormal CGA. In several studies a cut-off of 
2 abnormal scores was used (14;19;22;36;37). However the number of domains that were 
evaluated within the CGA differed. Moreover, in all of these studies, comorbidities 
were included in the reference CGA. Comorbidity overlaps with, but is distinct from, 
frailty. Comorbidity should be assessed routinely, independent of the results of 
screening or CGA. Specifically for the G8, when we considered using at least two 
abnormal scores, prevalence diminished from 88% to 60%, while specificity fell 
drastically (down to 50%) for a modest gain in sensitivity (97%).
Furthermore, as this study population is very specific, the obtained results might 
not be generalizable to other cancer populations.
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3. STRENGTHS OF THE THESIS
The field of geriatric oncology is evolving. Recently, some major studies were pu-
blished on the relevance of CGA in older cancer patients. Some of these studies also 
included a significant number of patients with haematological malignancies. This 
thesis however has been one of the few research projects dedicated solely to (ol-
der) patients with haematological malignancies. Although our findings on the G8 
are consistent with those published by Soubeyran et al. who examined a mixed 
oncology population (20), this distinction from patients with solid tumours is neces-
sary if only because of the distinction in treatment goals. Treatment of a haemato-
logical malignancy, in contrast with solid tumours, intends at haematological toxi-
city. Other treatment goals imply other chemotherapeuticals and therefore different 
interactions and side effects, e.g. malnutrition, can be expected.
Second, we have demonstrated that a standardized approach by means of a CGA 
seems useful and provides insight in some formerly unidentified problems. Although 
time-consuming, we were able to assess every patient before start of therapy, even 
in patients in whom initiation of therapy was urgent.
Third, we were the first to validate the G8 as a screening tool in a population of ol-
der patients with only haematological malignancies. Moreover, we made a first 
attempt to explore the possibilities of HGS as a single marker of frailty. 
4.  CLINICAL IMPLICATIONS
During the course of this project, a closer collaboration developed between the team 
members of the departments of haematology and geriatrics. Meanwhile, screening 
and assessment in hospitalized older patients with haematological malignancies be-
came “standard of care” and is integrated in the way of working of the internal liaison 
team. This intensive collaboration has led also to cross-pollination of expertise in this 
specific population. Furthermore, attempts have been made to integrate our findings 
in daily routine (e.g. screening of cancer patients with G8 instead of Geriatric Risk 
Profile (GRP)) and to set up new research to tackle some of the encountered problems 
(e.g. the use of START/STOPP criteria in the light of polypharmacy).
5. FUTURE PERSPECTIVES
The number of older patients with a haematological malignancy will further incre-
ase in the next decades, due to aging of the population. Similarly, the number of 
frail patients will continue to grow. 
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Keeping in mind the time-investment needed to perform a CGA, future studies 
should focus on screening tools allowing an optimal selection of patients for further 
geriatric evaluation. Different tools with good sensitivity are already available. Now 
research should focus on the optimization of specificity and negative predictive 
value. Instead of developing new screening tools, combining existing tools in a flow 
diagram, might prove a valuable option.
Furthermore, the potential of HGS as a marker of increasing frailty during treat-
ment should be further explored. Declining HGS below the proposed cut-points 
could be an indicator for renewed geriatric evaluation.
Growing evidence is available that geriatric parameters should be considered when 
planning cancer treatment. Studies nowadays are primarily focusing on treatment 
adaptations, with alterations in dose, frequency, or inclusion of less toxic agents. 
Geriatricians aim for a more holistic approach including geriatric interventions 
tailored to the results of the CGA. In the general geriatric population, these inter-
ventions, linked with follow-up, have proven their effectiveness in improving func-
tional status and survival. A SIOG task force has been established to review availa-
ble data on geriatric interventions in cancer patients. Ten articles and 5 abstracts 
have been identified, some of which suggest a positive impact on the patient’ s 
condition and outcome. Studies however are small, and very heterogeneous in pa-
tients as well as in interventions (case management type interventions, exercise-ba-
sed interventions, nutritional interventions, interventions for prevention of deliri-
um, chemotherapy toxicity, or post-operative pain, and quality of life interventions), 
and with different endpoints (6). As yet no recommendations have been published. 
Meanwhile, geriatric interventions currently proven beneficial in the general popu-
lation can be applied, keeping in mind some disease-specific limitations. In future 
research, a well-defined impairment in a CGA domain, an appropriate selection of 
patients, an appropriate intervention and a well-defined outcome measure seem 
crucial to achieve usable conclusions. Furthermore, one should focus on the incor-
poration of CGA results and interventions into an individualized treatment plan for 
frail older patients.
After all, optimizing the overall condition of a frail older patient with a haematolo-
gical malignancy might indicate the difference between full therapy and downgra-
ding of treatment or merely supportive care.
Briefly, haematologists are increasingly confronted with older patients, characte-
rized by decreased physiological reserves and an increased vulnerability to adver-
se outcomes. Adequate screening tools allow a better selection of patients in need 
of further geriatric evaluation. CGA hereby does reveal additional health problems, 
also in patients with haematological malignancies. Particular attention should be 
paid to nutrition and polypharmacy. Elaboration of multidisciplinary care pathways 
and close collaboration between team members of the departments of haemato-
logy and geriatrics are of vital importance to tackle some currently unmet needs. 
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Samenvatting
Er is een belangrijke toename van de groep ouderen met kanker door de vergrijzing 
van de bevolking. Ouderen vormen echter een zeer heterogene groep met belangrij-
ke verschillen in levensverwachting en functionaliteit tussen leeftijdsgenoten. Bijge-
volg kunnen de behandelingsrichtlijnen, zoals deze worden gehanteerd bij jongere 
individuen, niet zomaar doorgetrokken worden naar de groep van ouderen. Het doel 
van deze doctoraatsthesis was dan ook om na te gaan of een geriatrische benadering 
en meer specifiek het gebruik van een CGA een meerwaarde kon betekenen in de 
selectie van patiënten met een geriatrisch profiel, in de detectie van geriatrische 
syndromen en in de keuze en de uitkomst van de ingestelde behandeling.
In deze thesis toonden we aan dat aan de hand van een CGA, ook in patiënten met 
een hematologische maligniteit, vooraf niet gekende problemen konden worden 
gedetecteerd. Een ruime meerderheid van de oudere patiënten vertoont bij scree-
ning een risico op ondervoeding of scoort ondervoed. Gezien de bewezen negatie-
ve impact van ondervoeding op een oncologische behandeling zijn regelmatige 
opvolging en het introduceren van gerichte interventies in samenspraak met een 
diëtiste essentieel, ook al is op heden de doeltreffendheid van deze interventies 
nog onvoldoende bewezen.
Uit geriatrische evaluatie in deze thesis bleek ook duidelijk dat een behandeling met 
chemotherapie, en inherent hieraan het gebruik van supportieve medicatie, leidt 
tot polyfarmacie en frequente wijzigingen in het medicatieschema. Hierdoor is meer 
dan de helft van de patiënten niet langer in staat zelfstandig zijn medicatie klaar te 
zetten en in te nemen. Rekening houdend met het feit dat vele ouderen alleenstaand 
zijn of een partner hebben van dezelfde leeftijd dient in het behandelingstraject 
van deze patiënten op een gestructureerde manier, en bij herhaling, te worden ge-
peild naar de functionele autonomie van patiënten met betrekking tot medicatie.
Tijdens het onderzoek werd niet alleen gekeken naar de aanwezigheid van typisch 
geriatrische syndromen, maar werd ook gefocust op een correcte selectie van pa-
tiënten. Een CGA is immers zeer tijdrovend en niet voor iedere patiënt noodzakelijk. 
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Binnen de oncologie wordt gepleit voor een twee stappenbenadering waarbij pa-
tiënten eerst gescreend worden op de aanwezigheid van een geriatrisch profiel en 
pas in tweede tijd, indien de screening positief uitvalt, worden doorverwezen voor 
een CGA. Tijdens de studie werden twee screeningsinstrumenten beoordeeld op 
hun waarde. De G8 (met een afkapwaarde van ≤14) kon worden gevalideerd voor 
oudere patiënten met een hematologische maligniteit. In tegenstelling tot de G8, 
die is opgebouwd uit 8 vragen, is handgrijpkracht een performantiemaat waardoor 
men een meer objectieve weergave verkrijgt van de functionele mogelijkheden van 
een patiënt. In vergelijking met gezonde ouderen is de handgrijpkracht bij ouderen 
met hematologische maligniteiten lager, en dit al voor de start van de behandeling. 
Gebruik makend van een Martin vigorimeter werden, binnen de krijtlijnen van deze 
thesis, minimumwaarden voor handgrijpkracht berekend voor mannen en vrouwen. 
Alle patiënten met een lagere handgrijpkracht zouden moeten worden doorver-
wezen voor verdere geriatrische evaluatie. 
Deze thesis vormt slechts een eerste aanzet in het onderzoek naar de multidisci-
plinaire aanpak van oudere patiënten met hematologische maligniteiten. Verder 
onderzoek moet zich richten, enerzijds op interventies die, voor de start van de 
behandeling, de functionaliteit van de kwetsbare patiënt kunnen optimaliseren, en 
anderzijds op nieuwe behandelingsmodaliteiten waarin de bevindingen van het 
geriatrisch bilan worden meegenomen. Integratie van de resultaten van beide on-
derzoekslijnen zou uiteindelijk moeten leiden tot een behandelingsplan op maat 
van de individuele patiënt. 
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Summary
A significant increase has been seen in the number of older patients with cancer due 
to population ageing. Ageing however is a highly individualized and very heterogene-
ous process with a broad spectrum ranging from older persons who are functional-
ly independent to those who are at high risk of functional decline and mortality and 
all the others in between. Fit older patients should logically receive the same treat-
ment as their younger counterparts. The main problem however is the group of frail 
patients at increased risk for treatment complications. The main aim of this doctoral 
thesis was to explore whether in older patients with haematological malignancies a 
geriatric approach, and in particular a comprehensive geriatric assessment (CGA), 
might be worthwhile in the selection of patients with a geriatric profile, in the detec-
tion of geriatric syndromes and in the prediction of patient outcomes.
In this thesis, we demonstrated that, also in patients with a haematological malig-
nancy, a CGA can identify previously unknown geriatric problems in an individual. 
Through nutritional screening a large majority of patients was identified with poten-
tial nutritional problems. Given the negative impact of malnutrition on an anticancer 
treatment, regular follow-up and implementation of specific interventions, in colla-
boration with a dietician, are essential, even though efficacy of these interventions 
has not yet been adequately proven.
Moreover, geriatric evaluation in this thesis has clearly proven that chemotherapy, 
and inherent use of supportive medication, leads to polypharmacy and frequent 
changes in medication regimen. Because of this, more than half of the patients are 
no longer able to manage their medication independently. As most older patients are 
living alone or are taken care of by a partner of the same age, their current care pa-
thway should include a structured and repeated evaluation of functional autonomy 
with regard to medication management. 
This thesis did focus not only on the detection of geriatric syndromes, but also on a 
correct selection of patients with a geriatric profile, as the administration of a CGA 
is time and staff-consuming. Therefore a two-step approach is proposed with the 
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use of a screening tool to identify those patients that subsequently would benefit 
most from a CGA. During the conduct of our study we tested the performance of two 
different screening tools. G8 (with a cut-off of ≤14) could be validated for use in older 
patients with haematological malignancies. In contrast with G8, an 8-item question-
naire, hand grip strength is a performance-based measure and therefore a more 
objective reproduction of a patient’s functional reserves. In contrast with healthy 
individuals, we found that hand grip strength was reduced in patients with haema-
tological malignancies, even before onset of treatment. Using a Martin vigorimeter, 
we also determined minimum values for hand grip strength in men and women. Be-
low these values, all patients should be referred for further geriatric evaluation.
This doctoral thesis should be considered a first onset in the development of a mul-
tidisciplinary approach in older patients with haematological malignancies. Further 
research should focus for one thing on interventions that, before start of treatment, 
can optimize the functional reserves of a frail patient, and for another thing on new 
treatment modalities incorporating the results of the CGA. Integration of the results 
of both lines of investigation should eventually lead to a treatment plan tailored to 
the individual patient.
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Dankwoord
Op het einde van een doctoraat hoort een dankwoord. Dit dankwoord kwam tot 
stand in stukjes. Er kwamen stukjes bij in een plotse bui van inspiratie of wanneer 
ik op wolkjes liep omdat alles ging zoals ik het wou. Vaker nog kwamen er stukjes 
bij wanneer het wat moeilijker liep en een woord, een gebaar of een stevige knuffel 
van familie, vrienden of collega’s mij telkens opnieuw deed beseffen door welke 
fijne mensen ik dag in dag uit omringd word.
Mijn dank gaat in de eerste plaats uit naar mijn promotor, prof. dr. Mirko Petrovic. 
Al van bij het begin van mijn aanstelling in het UZ Gent kwam van jou regelmatig de 
suggestie om eens te denken aan een onderwerp voor een doctoraat. Het heeft je 
jaren werk en wat extra grijze haren gekost, maar het is je gelukt. Door jouw niet 
aflatende overtuigingskracht, door je interesse in hoe het ervoor stond, door je 
motiverende woorden, door je beschikbaarheid, door je begrip en je flexibiliteit en 
door het delen van je kennis en ruime ervaring is mijn doctoraat vandaag een feit.
Toch zou dit werk er mogelijk vandaag nog niet zijn zonder de bezieling van mijn 
co-promotor, prof. dr. Luc Noens. Hematologie en geriatrie lagen, letterlijk en fi-
guurlijk, mijlenver van elkaar. Jouw bekommernis voor de oudere patiënt binnen 
de grote groep van patiënten met hematologische maligniteiten is een gedeelde 
bekommernis geworden en werd uiteindelijk het zo lang gezochte onderwerp van 
mijn doctoraat, een bij uitstek klinisch doctoraat, gericht op de kwetsbare patiënten 
die ons zo nauw aan het hart liggen. Bedankt voor die eerste stap, die geleid heeft 
tot een brug, figuurlijk (en intussen ook letterlijk) tussen onze diensten.
Geriatrie wordt zelden beschouwd als “topklinische” of “topreferente” zorg. Geria-
trie haalt zelden de nationale pers, behalve door het tekort aan geriaters. Wat ik 
nochtans als “top” ervaren heb, is het feit dat de directie van het UZ Gent, door de 
toekenning van een KOF-mandaat aan dit onderzoek, een signaal heeft gegeven 
dat ook in een universitair centrum met een zeer gespecialiseerde visie, ruimte is 
voor onderzoek naar verbetering van de zorg voor oudere patiënten. 
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En met dit KOF-mandaat kwam Rein, mijn steun en toeverlaat. Rein, we hebben 
ruim twee jaar hetzelfde bureau gedeeld. We hebben veel gebabbeld. We hebben 
nog meer gewerkt. Alleen dankzij jouw onvermoeibare en onvoorwaardelijke inzet 
konden de gegevens verzameld worden waarop dit proefschrift is gebaseerd. Jouw 
minutieuze registratie van elk detail in het verhaal van de patiënt liet mij toe om 
steeds een antwoord te krijgen op nieuwe vragen die opdoken, ook nadat onze 
wegen zich scheidden. Lieve Rein, zonder jou stond ik hier niet.
Stefanie, ook jou wil ik bedanken. Je was onontbeerlijk bij de statistische analyse van 
de gegevens en ik heb genoten van de momenten waarop we samenzaten om de re-
sultaten te interpreteren. Bovendien hebben jouw kritische opmerkingen bij het na-
lezen van de artikels dit werk zeker naar een hoger niveau getild. Het laatste artikel 
op ons beider naam beschouw ik dan ook als de kroon op onze samenwerking. 
Een woord van dank ook aan de voorzitter van de examencommissie, prof. dr. Dirk 
Cambier, evenals de leden van de examencommissie, prof. dr. Dominique Benoit, dr. 
Philip Debruyne, prof. dr. Patricia Devriendt, prof. dr. Johan Flamaing, prof. dr. Syl-
vie Rottey en prof. dr. Hans Wildiers. De constructieve opmerkingen en vooral ook 
de uitnodiging tot kritische reflectie heb ik ten zeerste gewaardeerd. 
Het afwerken van een doctoraat vraagt tijd, heel veel tijd; tijd die je niet altijd hebt 
als je daarnaast ook klinische taken hebt. Volgens mij zijn er weinigen die hierbij zo 
op hun collega’s kunnen rekenen als bij mij het geval was. Nele, als diensthoofd gaf 
je mij de mogelijkheid om wetenschappelijke tijd af te bakenen. Je had begrip voor 
mijn “nee” als ik een taak niet wou/kon opnemen en je ging op zoek naar ruimte in 
je eigen, overvolle agenda. Als bureaumaatje vormde jouw enorme hoeveelheid 
kennis voor mij tegelijkertijd een uitdaging en een inspiratiebron. Door jou als klank-
bord te gebruiken kwam ik regelmatig tot nieuwe inzichten. Wim, Ruth, Mirko, we-
tenschappelijke tijd kan je pas afbakenen als iemand anders je taken overneemt. 
Bedankt voor onze jarenlange, fijne samenwerking waarbinnen ik steeds een beroep 
kon en kan doen op jullie.
Mieke en Virgie, de laatste weken hebben jullie aan mij regelmatig de handen vol 
gehad, vooral met de praktische aspecten die de verdediging van een doctoraat 
met zich mee brengt. Wat ik ook vroeg, telkens werd ik ontvangen met een stra-
lende glimlach en ging ik terug buiten met een geruststellend “komt in orde”. Dank 
voor jullie gulle bijdrage aan mijn innerlijke rust. 
Ook Marc Dauwe wil ik niet vergeten. Door jouw interesse en betrokkenheid in dit 
project en de logistieke ondersteuning die je ons bood, kon dit project enkele maan-
den langer doorgaan dan oorspronkelijk gepland. Meteen wil ik hier ook alle pati-
enten en hun familie bedanken voor hun bereidheid om deel te nemen en ons een 
stukje van hun vaak kostbare tijd te gunnen.
Het realiseren van een doctoraat is een onvergetelijke ervaring die ik voor geen 
goud had willen missen. Toch ligt mijn hart bij de kliniek. Lieve collega’s van het 
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zorgprogramma voor de geriatrische patiënt, zowel hier als in Deinze, dank voor 
de warme zorg waarmee jullie, elke dag opnieuw, onze oudere patiënten omringen. 
Ik heb het gemist, meer dan ik kan zeggen, om volledig te kunnen opgaan in dit zor-
gende team. Ik kijk dan ook uit naar de dag van morgen.
Een speciaal woord van dank gaat vandaag naar mijn familie.
Papa, dank voor die fijne zondagen, dat telkens opnieuw thuiskomen in het warme 
nest waarin ik ben opgegroeid samen met mijn broers, en waar ik eventjes alle 
stress en deadlines kon laten voor wat ze waren.
Ook mijn schoonouders wil ik bedanken. Jullie staan reeds 10 jaar lang elke dag klaar 
om onze kinderen op te vangen na schooltijd of hen te vertroetelen als ze ziek zijn. 
Zonder jullie hulp zou ik er nooit in geslaagd zijn om werk en gezin, laat staan werk, 
gezin en een doctoraat, met elkaar te combineren. 
Naima, Alyssia, Alexandra en Anahita, ik word verondersteld te zeggen dat er nu 
betere tijden aanbreken. Ik heb van mijn collega’s begrepen dat de realiteit er toch 
enigszins anders uitziet en dat er na het beëindigen van een doctoraat meestal nog 
minder tijd overblijft. Maar net zoals dat tot nu toe het geval was, zullen de gezel-
lige babbels aan tafel, onze gesprekjes over de meest idiote onderwerpen net voor 
het slapen gaan en vooral jullie onuitputtelijke voorraad knuffels mij telkens op-
nieuw de energie geven om deze evenwichtsoefening tot een goed einde te brengen.
Ik eindig dit dankwoord bij de belangrijkste man in mijn leven. Lieve echtgenoot, aan-
gezien het niet altijd eenvoudig is om een gesprek te voeren te midden van onze immer 
rumoerige dochters, hebben we elkaar ook leren begrijpen zonder woorden. Toch wil 
ik jou vandaag heel speciaal zeggen: bedankt dat je samen met mij oud wil worden. 
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